

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The impact of incident syphilis infection on HIV-infected patients engaged in care.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021544
Article Type:	Research
Date Submitted by the Author:	18-Jan-2018
Complete List of Authors:	Lang, Raynell; University of Calgary Cumming School of Medicine, Department of Medicine Read, Ron; University of Calgary Cumming School of Medicine, Department of Medicine Krentz, Hartmut ; Alberta Health Services, S. Alberta HIV Clinic Peng, Mingkai; University of Calgary, Department of Community Health Sciences Ramazani, Soheil; Alberta Health Services, S. Alberta HIV Clinic Vu, Quang; Alberta Health Services, S. Alberta HIV Clinic Gill, M John; University of Calgary Cumming School of Medicine, Department of Medicine; Alberta Health Services, S. Alberta HIV Clinic
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5 **TITLE:** The impact of incident syphilis infection on HIV-infected patients engaged in care.  
6  
7

8 **AUTHORS:**  
9

10 Raynell Lang, Department of Medicine, University of Calgary, Calgary, Canada  
11

12 Ron Read, Department of Medicine, University of Calgary, Calgary STI Clinic Calgary, Canada.  
13

14 Hartmut B. Krentz, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
15

16 Mingkai Peng, Department of Community Health Sciences, University of Calgary, Calgary.  
17  
18

19 Canada.  
20

21 Soheil Ramazani, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
22

23 Quang Vu, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
24  
25

26 M. John Gill, Department of Medicine, University of Calgary, S Alberta HIV Clinic, Alberta  
27

28 Health Services, Calgary, Canada.  
29  
30  
31  
32

33 **CORRESPONDING AUTHOR:** M John Gill Department of Medicine 3330 Hospital drive  
34

35 NW Calgary Alberta T2N4N1 Telephone: 403 955 6315 Fax: 403 955 6333  
36

37 Email: John.Gill@albertahealthservices.ca  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** Syphilis is a global health concern with an estimated twelve million infections occurring annually. Due to the increasing rates of new syphilis infections being reported in HIV-infected patients, and their higher risk for atypical and severe presentations, periodic screening has been recommended as a routine component of HIV care. We aimed to characterize incident syphilis presentation, serologic features and treatment response in a well-defined, HIV-infected population over 11 years.

**Methods:** Since 2006, as routine practice of both the Southern Alberta Clinic (SAC) and Calgary STI Programs (CSTI) syphilis screening has accompanied HIV viral load measures every four months. All records of patients who, while in HIV care, either converted from being syphilis seronegative to a confirmed seropositive or were re-infected as evidenced by a four-fold increase in rapid plasma reagin (RPR) after past successful treatment, were reviewed.

**Results:** We identified 249 incident syphilis infections in 194 different HIV-infected individuals; 72% were initial infections whereas 28% were reinfections. Half (50.8%) of the infections were asymptomatic and identified only by routine screening. Symptomatic syphilis was more common when rapid plasma reagin (RPR) titers were higher ( $P=0.03$ ). In patients with repeat syphilis infection, a trend was noted favoring symptomatic presentation (62%,  $P=0.07$ ). All 10 patients with CNS syphilis involvement presented with an RPR titer  $\geq 1:32$ . Following syphilis infection a decline of 42 cells/mm<sup>3</sup> in CD4 ( $P=0.004$ ) was found, but no significant changes in viral load occurred. No association was found with the stage of syphilis or symptoms at presentation and ART use, CD4 count or virologic suppression.

1  
2  
3 **Conclusion:** Routine screening of our HIV-infected population identified many asymptomatic  
4 syphilis infections. The interaction of HIV and syphilis infection appears to be bidirectional with  
5 effects noted on both HIV and syphilis clinical and serological markers.  
6  
7  
8  
9  
10  
11

## 12 **ARTICLE SUMMARY**

### 13 **Strengths and limitations of this study**

- 14 1. All HIV and STI care in our region is highly centralized and coordinated allowing for  
15 detailed analyses of our population.  
16
- 17 2. Routine syphilis serology regardless of risk behaviors or symptomatology was obtained  
18 every four months in our HIV-infected population, allowing close monitoring of clinical  
19 characteristics, bidirectional interactions as well as inclusivity of incident syphilis  
20 infections.  
21
- 22 3. The study population, while comprehensive and representing a Canadian perspective, is  
23 from a single regional area and may not be representative populations elsewhere that  
24 have different rates of unprotected sexual activity and both prevalent HIV and syphilis  
25 infections. In addition, access to care varies between centers and populations and our  
26 rates and identification methods may not precisely match others.  
27
- 28 4. This study may underestimate the clinical impact of syphilis in an HIV-infected  
29 population as patients not accessing care and individuals infected but lost to follow up or  
30 moving out of Alberta were not analyzed.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION:

Syphilis continues to be a major public health concern globally, with an estimated twelve million new infections annually[1]. HIV-infected individuals are eight times more likely to become infected with syphilis than the general population[2]. In 2016, in Alberta Canada, over 25% of all new syphilis infections occurred in men who have sex with men (MSM) co-infected with HIV[3]. It has been suggested that increased use of social media including websites and mobile apps targeted towards meeting sex partners as well as serosorting (finding sex partners with the same HIV serostatus for unprotected sex), may be contributing to the rebound of high risk sexual activity in this population[2, 4]. The suppression of HIV viral replication using antiretroviral therapy (ART) resulting in minimal risk for sexual transmission of HIV has received legal recognition in Canada[5]. This reduced legal risk for transmission among virologically suppressed individuals (HIV viral load <1,000 copies/mL) may also be leading to increased high risk sexual behavior and contributing to the epidemic of syphilis among the HIV-infected population[4, 5]. HIV PrEP use was not extensively used in the community during the study period and any potential role seemed unlikely.

Syphilis infection in HIV-infected patients can present in atypical or aggressive forms, such as ulcerative skin lesions, persistent chancres, gummatous disease and neurosyphilis[6-9]. Sexually transmitted infections (STIs) may increase risk of HIV acquisition via interruption of mucosal barriers and increased viral shedding[9-11]. It has also been suggested that both therapeutic and prophylactic ART may inadvertently increase the incidence of syphilis by altering innate and acquired immune responses that may enhance susceptibility to syphilis infection[12]. Due to these increasing rates of syphilis and the higher likelihood of atypical and severe presentation,

1  
2  
3 routine periodic screening (2-4 times annually) of HIV-infected persons has been  
4  
5 recommended[4, 9, 13].  
6  
7  
8  
9

10 The aim of this retrospective cohort study was both to characterize syphilis presentation,  
11 serologic features and treatment response in a large cohort of HIV-infected individuals engaged  
12 in HIV care and receiving regular syphilis testing, as well as to examine the effect of incident  
13 syphilis on HIV disease markers.  
14  
15  
16  
17  
18  
19  
20

## 21 **METHODS**

### 22 **Study Population**

23  
24 The Southern Alberta Clinic (SAC) and Calgary STI Clinic (CSTI) provide exclusive care to all  
25 HIV-infected individuals living in southern Alberta, Canada. In a quality assurance project  
26 (approved by University of Calgary Bioethics committee) at both programs between January 1,  
27 2006 and December 31, 2016, routine syphilis serology regardless of risk was ordered every four  
28 months accompanying HIV viral load testing. The records of all incident syphilis infections  
29 occurring in HIV-infected patients were reviewed. Every indeterminate or positive syphilis  
30 serology for a SAC patient was discussed with or referred to CSTI at the time of testing.  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43

44 All individuals with at least one visit between January 1, 2006 and December 31, 2016 were  
45 studied. Patients were followed until December 31, 2016 or until they moved, died or were lost-  
46 to-follow-up. All patients, who while in HIV care, converted from being seronegative for  
47 syphilis to a confirmed positive status or were re-infected with syphilis were reviewed through  
48 the SAC database and a CSTI chart review.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Diagnosis

The syphilis screening algorithm and confirmatory testing was achieved using indirect serologic methods. Initially screening for syphilis was done with the non-treponemal rapid plasma reagin (RPR), however in 2008 the screening test was changed to an enzyme immunoassay (EIA), a treponemal test. The RPR continued to be used as a confirmatory test as well as for monitoring response to therapy[13, 14]. In Calgary, the secondary confirmatory test was either the fluorescent treponemal antibody absorption test (FTA-ABS) or the line immunoassay (INNO-LIA)[15]. Repeat syphilis episodes were identified by a four-fold increase in RPR after a prior documented successful treatment course for syphilis and were evaluated and staged by an STI specialist (RR). Neurosyphilis was documented by a positive CSF-VRDL (Venereal disease research laboratory) on lumbar puncture as well as evaluated by an STI specialist (RR).

## Data Collection

Detailed standardized information was collected by one physician (RL), through a comprehensive review of both SAC and CSTI charts and databases. Multiple data sources in these records were accessed including nursing interviews, social work reports, self-administered questionnaires, laboratory reports, and physician notes.

From the SAC database, we identified the number of syphilis tests performed yearly at the clinic per patient as well as the interval between tests. Demographic data was collected at the time of HIV diagnosis and incorporated into the SAC database. These data included: gender (i.e. male, female, transgendered), self-reported ethnicity (i.e. Caucasian, Indigenous,



1  
2  
3 African/Caribbean/Black (ACB), Other) and most likely HIV exposure risk (i.e. MSM, HET-  
4  
5 heterosexual sex, PWID (persons who inject drugs), and other).  
6  
7  
8  
9

10 The stage of syphilis (i.e. primary, secondary, early latent, late latent) and symptomatology at  
11 presentation (i.e. rash, ulcer/lesion, flu-like illness, condylomata, lymphadenopathy, neurological  
12 (tinnitus/ocular), asymptomatic, other) were collected via review of CSTI charts. All episodes of  
13 syphilis were staged by an STI specialist (RR). Prior history of comorbid infections including  
14 *Neisseria gonorrhoeae* and *Chlamydia trachomatis* were self-reported and documented in CSTI  
15 charts at the time of syphilis diagnosis.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 The initial RPR was documented at the time of syphilis diagnosis and recorded in CSTI charts.  
27 HIV viral load and CD4 counts were measured at the time of syphilis diagnosis and subsequently  
28 at the next routine HIV follow-up appointment. HIV viral suppression was defined as a plasma  
29 viral load <40 copies/mL. Treatment modalities (i.e. Benzathine Penicillin, Doxycycline,  
30 Penicillin G) and response to therapy were reviewed retrospectively through a comprehensive  
31 chart review. All data was anonymized prior to analysis.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 **Statistical Analysis**

43 Demographic and clinical factors of patients were compared using chi-square test. Viral load and  
44 CD4 counts prior to and following episode of syphilis infection were compared using linear  
45 mixed effect model while accounting for repeated measurement and more than one episode for  
46 some patients. Subgroup analyses were performed on neurosyphilis infections and those with  
47 repeat episodes of syphilis. Patients not accessing care and individuals infected but lost to follow  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 up or moving out of Alberta were not analyzed. All statistical analysis was performed using R (R  
4 Development Core Team, 2005). All charts were created with Microsoft Excel and R.  
5  
6  
7  
8  
9

## 10 **RESULTS:**

### 11 **Demographics**

12  
13  
14 Between 2006 and 2016, there were 20,203 syphilis tests done on a total of 2,448 patients who  
15 attended at least one regular SAC visit during that time. On average there were 180 days between  
16 each syphilis test per patient. The average number of syphilis screening tests that were done per  
17 patient each year over the 11-year period was 2.1. In 2006 the average number of tests per year  
18 was 1.3, whereas in 2016 this was 2.8. For high risk patients (MSM) screening rates were more  
19 frequent with the average testing over 11 years being 2.4 tests per year.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30  
31 Of the 2,448 HIV-infected individuals at SAC and CSTI programs encompassing 15,175 person  
32 years of follow up between 1/1/2006 and 12/31/2016, we identified 360 incident syphilis  
33 infections, meeting our broad study criteria, occurring in 305 different patients. One hundred and  
34 eleven syphilis episodes were excluded; 38 were confirmed false positive screening tests, in 41  
35 infections the patient, while being tested in Alberta, had moved out of province resulting in  
36 incomplete availability of their clinical data, and in 32 episodes, there was inadequate basic  
37 information available for study inclusion. We therefore analyzed 249 episodes in 194  
38 individuals.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 Of the 249 infections, 178 (72%) were first episode of a syphilis infection, whereas the  
52 remaining 71 (28%) were repeat episodes. Concurrent STI's included; 32% of cases having a  
53  
54  
55  
56  
57  
58  
59  
60

self-reported history of *Neisseria gonorrhoeae* and 24% having had *Chlamydia trachomatis* infection. The annual incidence rates of syphilis in our HIV-infected population tripled from 2011, 8.08/1000 patient-years (95% confidence interval (CI): 4.14-14.75), to 27.04 per 1000 person-years (95% confidence interval (CI): 19.45-36.76) in 2016. The characteristics of the 194 individuals included in this analysis are described in table 1.

**Table 1: Characteristics of HIV+ patients regularly followed at the Southern Alberta Clinic between 1/1/2006 and 12/31/2016 comparing patients who were negative for syphilis (Syphilis Neg) to patients who ever tested positive for syphilis (Syphilis Pos).**

N (%)	Syphilis Neg 2254 (92.1)	Syphilis Pos 194 (7.9)	P-value
<b>Age at HIV Diagnosis (years)</b>			
Mean (range)	35 (1-79)	35 (16-69)	0.893
<30	813 (36.1)	75 (38.7)	0.801
30-39	802 (35.6)	66 (34.0)	
40-49	438 (19.4)	37 (19.1)	
≥50	201 (8.9)	16 (8.3)	
<b>Gender</b>			
Male	1675 (74.3)	183 (94.3)	<.001
Female	572 (25.4)	11 (5.6)	
Transgendered	7 (0.3)	0 (0.0)	
<b>Self-reported Ethnicity<sup>1</sup></b>			
Caucasian	1259 (56.0)	140 (72.2)	<.001
Indigenous	216 (9.6)	6 (3.1)	
ACB	536 (23.8)	24 (12.4)	
Other	243 (10.8)	22 (11.3)	
<b>Most Likely HIV Exposure Category<sup>2</sup></b>			
MSM	915 (40.6)	145 (74.4)	<.001
HET	512 (22.7)	14 (7.2)	
PWID	731 (32.4)	30 (15.6)	
Other	96 (4.3)	5 (2.6)	

<sup>1</sup>Indigenous people includes Aboriginal, Metis and Inuit; ACB includes African, Caribbean, Black; Other includes IndoAsian, Hispanic, East Asian, and other

<sup>2</sup>MSM=self-reported men who have sex with men identification; HET=self-reported heterosexual identification; PWID=self-reported intravenous drug use identification; Other HIV Risk factor behavior includes: blood transfusions, hemophiliac, neonatal, postnatal infection, unknown or not reported.

## Symptomatology

### *Asymptomatic syphilis episodes*

Just over half of the episodes (50.8%) of incident syphilis infections were asymptomatic and identified by routine screening (Figure 1). RPR titers were higher in patients with symptomatic versus asymptomatic syphilis ( $P=0.03$ ) (Figure 2). The majority of episodes with an initial RPR of 1:4 or less were asymptomatic (71%). Those with lower CD4 ( $<200$  cells/mm<sup>3</sup>) counts at syphilis diagnosis had no significant differences in symptomatology as opposed to those with CD4 counts  $>200$  cells/mm<sup>3</sup> ( $P=0.65$ ). Comparing symptomatic versus asymptomatic episodes neither virologic suppression of HIV nor ART influenced the individual's likelihood to present with any of the symptoms of syphilis at diagnosis.

### *Symptomatic syphilis episodes*

The most common presenting symptom was rash (23%), followed by skin lesion or ulceration (18%). Uncommon presentations included lymphadenopathy, flu-like illness, condylomata lata and neurological symptoms (Figure 1).

Those with primary syphilis presented most commonly with skin ulceration/lesion (57%) and in those with secondary syphilis the presentation was a rash (76%). However, 15% of those diagnosed with secondary syphilis also complained of skin ulceration or lesion in addition to a rash. Although rare overall as presenting symptoms, lymphadenopathy (86%), flu like illness (50%) and condylomata (100%) were most seen in primary syphilis.

### Stage of Syphilis

Both ART and virologic suppression of HIV had no association with the individual's stage of syphilis at diagnosis. Of those diagnosed with late latent syphilis, 98% had an initial RPR of 1:16 or less. Patients with secondary syphilis tended to present with a higher RPR with 33% having an RPR of 1:256 or higher.

Since 2008, the proportion of late latent syphilis infections diagnosed among our HIV-infected patients in care had decreased from 44% to 4.4% (Figure 3). Caucasian individuals were more likely to present with primary (24%) or secondary (28%) syphilis ( $P < 0.001$ ), whereas the non-Caucasian population were more likely to present with latent disease (41%) with only 26% having either primary or secondary syphilis ( $P < 0.001$ ). In males, the majority of infections were early latent (34%) and the minority being late latent (18%). However, in females 77% of infections were late latent.

### Serologic Effect of Syphilis on HIV

As the interaction of HIV and syphilis infection may be bidirectional we explored CD4 and viral load response to syphilis infection. A significant decrease in CD4 count of 42.2 cells/mm<sup>3</sup> ( $P = 0.004$ ) was noted in association with syphilis coinfection (Figure 4). No change in HIV viral load was noted in association with syphilis infection ( $P = 0.47$ ) (Figure 5).

### Serologic Effect of HIV on Syphilis

Nearly half (49%) of all patients presented with RPR (non-treponemal) titers between 1:32-1:128. There were two episodes presenting with an initial RPR greater than 1:2048; both patients

1  
2  
3 were not HIV virologically suppressed (HIV plasma viral load >1,000 copies/mL) at the time of  
4 syphilis infection (Figure 2). The individuals viral load (P=0.82) or CD4 count (P=0.48) did not  
5  
6 appear to have any correlation with the initial RPR titer. Due to the small number of patients in  
7  
8 this group (n=48) we were unable to evaluate if absence of ART had an impact on RPR titer.  
9  
10  
11  
12  
13

### 14 **Repeat Episodes of Syphilis**

15  
16 In patients with repeat syphilis infection, a trend (P=0.07) was noted favoring a symptomatic  
17 presentation (62%). Rash and skin lesion/ulceration also remained the most common complaint  
18  
19 (Figure 6). Repeat episodes of syphilis were much less likely to have late latent disease (3%) and  
20  
21 instead more likely to have primary (28%), secondary (28%) or early latent disease (39%). Of  
22  
23 those with a repeat syphilis episode, 29% had RPR titers over 1:256, compared to 18% of the  
24  
25 total population in the study. Only 10% of the patients with prior syphilis exposure had an initial  
26  
27 RPR less than 1:4 compared to 32% of the patients with initial infection, however this did not  
28  
29 reach significance (P=0.604).  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Neurosyphilis**

39  
40 Ten patients (4%) experienced CNS involvement with a positive CSF-VDRL on lumbar  
41  
42 puncture. Ocular symptoms with blurred vision or painless visual loss occurred in four patients,  
43  
44 tinnitus in three patients and three were asymptomatic. Nine patients were male and Caucasian  
45  
46 with eight being >40 years old. Eight were initial syphilis episodes and two were reinfections.  
47  
48 Seven of the ten patients were on ART, five were virologically suppressed with seven having a  
49  
50 CD4 count > 500 cells/mL. The RPR titer at diagnosis was  $\geq 1:32$  in all episodes of CNS  
51  
52 involvement with five having an RPR titer of  $\geq 1:512$  and two of these episodes diagnosed with  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 initial RPR titers of 1:8192. These RPR titers were much higher than any other symptom  
4 presentation or stage of syphilis ( $P < 0.001$ ) (Figure 2). All patients with CNS involvement were  
5 treated successfully, based on both clinical and serologic response, with intravenous penicillin G  
6 for 14 days.  
7  
8  
9  
10  
11  
12  
13

### 14 **Treatment**

15  
16 A standard three-week course of weekly intramuscular injections of Benzathine penicillin  
17 (2.4MU per dose) was used for 77% of the patients, while 10% received an oral course of  
18 doxycycline, and 10% received a combination of the two medications. Successful completion of  
19 the full course of treatment was achieved in 94% (with 5% requiring retreatment from inadequate  
20 initial adherence and 1% never completing their full course).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

### 31 **DISCUSSION:**

32  
33 Our introduction in 2006 of syphilis screening to accompany routine HIV viral load testing  
34 allowed for the identification and analysis of incident syphilis infections in the HIV population in  
35 care in Calgary, Alberta. Our results confirm prior findings that co-infection with HIV can result  
36 in atypical or aggressive syphilis presentations[6-9]. Compared to non HIV-infected populations,  
37 prior studies have found higher rates of asymptomatic primary syphilis, which may result in  
38 missed diagnosis and increased episodes of secondary syphilis[9, 17]. In our study population,  
39 50.8% (135) syphilis episodes were asymptomatic at presentation, including 21% (10) of the  
40 primary syphilis infections. Braun et al. recently published a study evaluating symptoms of  
41 syphilis in 19 HIV-infected individuals and found the rate of asymptomatic syphilis infections in  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 HIV-infected individuals to be 40%[16]. Routine syphilis screening has been confirmed to be  
4  
5 effective in detecting early asymptomatic syphilis in HIV-infected outpatients[17].  
6  
7

8  
9  
10 Our study demonstrated a decline in latent syphilis between 2008 (44%) and 2016 (4%). In 2008,  
11  
12 the high numbers of latent syphilis may be reflective of a change to the testing algorithm for  
13  
14 syphilis, from an initial RPR to enzyme immunoassay (EIA), resulting in an improved test  
15  
16 sensitivity and the identification of latent syphilis[14, 15]. While latent episodes have been  
17  
18 steadily declining since 2013, the number of primary syphilis diagnoses are increasing. Through  
19  
20 regular syphilis screening in this HIV-infected population, earlier detection of syphilis in its  
21  
22 primary stage has been achieved, leading to prompt therapy, which may decrease ongoing  
23  
24 syphilis transmission[4].  
25  
26  
27

28  
29  
30 The interaction of HIV and syphilis infection appears to be bidirectional with effects noted on  
31  
32 both HIV and syphilis serologic markers[9]. False positive syphilis testing among non-  
33  
34 treponemal antibody is more common in the HIV-infected patients[9, 14, 18]. A rate of  
35  
36 approximately 11% is reported by Rompalo et al. which is very similar to our findings (10.5%),  
37  
38 however this study was done in 1992 and had fewer HIV-infected participants[18]. Prior studies  
39  
40 have reported that syphilis infection may increase HIV viral load and decrease CD4 count[19-  
41  
42 21]. We observed a statistically significant decrease in CD4 count associated with incident  
43  
44 syphilis infections, but no change in viral load was noted. This difference in findings compared  
45  
46 with past studies may in part, be explained by the majority of our patients being on ART, which  
47  
48 are perhaps more potent in suppressing viral replication.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 An increased prevalence of neurologic manifestations has been reported in HIV-infected  
4 individuals[2, 4]. Approximately one third of any patient with early syphilis will have  
5  
6 treponemal invasion into their CNS regardless of their HIV status[4]. However, an increased rate  
7  
8 of early neurosyphilis among HIV-infected individuals has been noted and may be linked to the  
9  
10 patient's inability to control the CNS infection rather than increased invasion into the CNS[4,  
11  
12 22]. Our data revealed 10/249 (4%) of the syphilis episodes diagnosed in our HIV-infected  
13  
14 cohort were neurosyphilis.  
15  
16  
17  
18  
19  
20

21 Neurosyphilis is more likely to be asymptomatic in HIV co-infected individuals and therefore a  
22  
23 more difficult diagnosis [4]. Three of our ten neurosyphilis episodes were indeed asymptomatic.  
24  
25 As a response to the absence of symptoms CDC guidelines recommend HIV-infected individuals  
26  
27 who receive a diagnosis of late latent syphilis, unknown duration of disease, have neurologic  
28  
29 symptoms or treatment failure should undergo CSF evaluation[4, 23]. It is controversial whether  
30  
31 all HIV co-infected individuals require evaluation for neurosyphilis at the time of syphilis  
32  
33 diagnosis[4].  
34  
35  
36  
37  
38  
39

40 Recent data suggests that there is an association with RPR titers  $\geq 1:32$  and laboratory defined  
41  
42 neurosyphilis (sensitivity of 100%, specificity of 40%)[24, 25]. This is in keeping with our study  
43  
44 findings, deducing that lumbar puncture could be restricted to the subgroup of patients with  
45  
46 neurologic manifestation or a serum RPR of  $\geq 1:32$ [24, 25]. Prior studies have found that patients  
47  
48 with CD4 counts  $< 350\text{mm}^3$ , may be at increased risk for neurosyphilis, however we identified no  
49  
50 specific correlation[4, 25, 26]. We did note that five of the individuals with neurosyphilis were  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 not HIV virologically suppressed, suggesting that there may be a link between increased HIV  
4  
5 viral loads and neurosyphilis, however this requires further study.  
6  
7  
8  
9

### 10 **CONCLUSIONS:**

11  
12 Through routine screening of an HIV-infected population engaged in care, many asymptomatic  
13  
14 syphilis episodes were identified and treated resulting in a shift in diagnostic stage of syphilis  
15  
16 infection from latent to primary and a theoretical decrease in ongoing transmission. Individuals  
17  
18 with symptomatic syphilis infections were more likely to have higher RPR titers and those with  
19  
20 highest RPR titers were at greater risk of neurosyphilis. ART, CD4 count and virologic  
21  
22 suppression of HIV had no association with the individual's stage of syphilis or symptoms at  
23  
24 diagnosis. Syphilis infection was associated with a temporary decrease in CD4 count with no  
25  
26 impact on HIV viral load. As the rates of syphilis rise among the HIV-infected population,  
27  
28 ongoing vigilance in screening and treatment is required in addition to further examination of co-  
29  
30 infection interactions.  
31  
32  
33  
34  
35  
36  
37

### 38 **KEY MESSAGES**

- 39  
40 1. Through routine syphilis testing of an HIV-infected population many asymptomatic  
41  
42 syphilis episodes were detected and treated.  
43
- 44  
45 2. Symptomatic individuals at diagnosis were more likely to have higher RPR titers.  
46
- 47  
48 3. Syphilis coinfection was associated with a temporary decrease in CD4 count, but no  
49  
50 change in viral load was noted.
- 51  
52 4. Patients with neurosyphilis were more likely to have higher RPR titers at diagnosis with  
53  
54 no cases occurring in patients with titers <1:32.  
55  
56  
57  
58  
59  
60

**FIGURE LEGENDS:**

Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected population.

Figure 2: Percentage of syphilis episodes in individuals with HIV based on their initial RPR titer and divided by symptoms of syphilis at presentation. Individuals who had symptoms compared to those that did not were more likely to have a higher initial RPR ( $P=0.0339$ ). Those with neurologic symptoms had a significant elevation of their initial RPR titers compared with all other symptoms ( $P<0.001$ ).

Figure 3: There is an increased number of incident syphilis infections among HIV positive individuals who are active in care programs from 2006-2016. There is an apparent trend of decreased proportion of late latent disease.

Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2 cells/mm<sup>3</sup> ( $P=0.004$ ).

Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis co-infection ( $P=0.47$ ).

Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by repeat infections. There is a trend demonstrating that individuals with repeat syphilis infections

1  
2  
3 were more likely to be symptomatic on presentation, however this did not reach significance  
4  
5 (P=0.0799).  
6  
7  
8  
9

## 10 **DECLARATIONS:**

11  
12  
13  
14 **Ethics approval and consent to participate:** Ethics approval was obtained through the  
15  
16 University of Calgary Bioethics committee as a quality assurance project through A Project  
17  
18 Ethics Community Consensus Initiative (ARECCI). Approval was granted both verbally and  
19  
20 written on Aug 23, 2016.  
21  
22  
23

24 **Data sharing:** The datasets generated and/or analyzed during the current study are not publicly  
25  
26 available due to patient confidentiality. The sensitive nature of this information as well as the  
27  
28 relatively small number of patients included in this dataset may lead it to be identifying and  
29  
30 therefore does not allow this dataset to be made public.  
31  
32  
33

34 **Funding:** No funding was received for this work.  
35  
36  
37

38 **Conflicts of interest:** We have no relevant conflicts of interest to disclose.  
39  
40

41 This work was previously presented at ID week 2017 in San Diego, California.  
42  
43  
44

45 **Authors' contributions:** RL, RR, HK and JG were involved in study design, data extraction,  
46  
47 data analysis, drafting and final review of this work. SR, MP, and QV were involved in data  
48  
49 extraction, data analysis and final review of this work. All authors read and approved the final  
50  
51 manuscript.  
52  
53  
54  
55  
56  
57  
58  
59  
60

**REFERENCES:**

1. World Health Organization, Dept of Reproductive Health and Research. Global incidence and prevalence of selected curable sexually transmitted infections – 2008. 2012. Available at: <http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/>. Date accessed: Dec 6, 2017.
2. Karp G, Schleffer F, Jotkowitz A, *et al*. Syphilis and HIV co-infection. *Eur. J. Intern. Med* 2009;**20**:9-13.
3. Gratrix J. personal communication Dec 6, 2017. Alberta Health Services, STI Centralized Services.
4. Zetola NM, Klausner JD. Syphilis and HIV Infection: An Update. *CID* 2007;**44**:1222-8.
5. R. v. Mabior, 2012 SCC 47, [2012] 2 S.C.R. 584. Available at: <https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/10008/index.do>. Date accessed: Dec 1, 2017.
6. Rompalo AM, Joesoef MR, O'Donnell JA, *et al*. Clinical Manifestations of Early Syphilis by HIV Status and Gender: Results of the Syphilis and HIV Study. *Sex Transm Dis* 2001;**28**(3): 158-65.
7. Marra CM, Tantaló LC, Sahi SK, *et al*. Reduced Treponema pallidum-Specific Opsonic Antibody Activity in HIV-Infected Patients with Syphilis. *J Infect Dis* 2016;**213**:1348-54.
8. Collis TK, Celum CL. The Clinical Manifestations and treatment of Sexually Transmitted Diseases in Human Immunodeficiency Virus-Positive Men. *Clin Infect Dis* 2001;**32**:611-22.
9. Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. *Lancet Infect Dis* 2004;**4**:456-66.

10. McCoy SI, Eron JJ, Kuruc JD, *et al.* Sexually transmitted infections among patients with acute HIV in North Carolina. *Sex Transm Dis* 2009;**36**(6):372–4.
11. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. *Sex Transm Infect* 1999;**75**:3–17.
12. Rekart ML, Ndifon W, Brunham RC, *et al.* A double-edged sword: does highly active antiretroviral therapy contribute to syphilis incidence by impairing immunity to *Treponema pallidum*? *Sex Transm Infect* 2017;**0**:1-5.
13. Branger J, Van Der Meer JT, Van Ketel RJ, *et al.* High Incidence of Asymptomatic Syphilis in HIV-Infected MSM Justifies Routine Screening. *Sex Transm Dis* 2009;**36**(2):84-5.
14. Ratnam S. The laboratory diagnosis of syphilis. *Can J Infect Dis Med Microbiol* 2005;**16**(1):45-51.
15. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted Infections: Syphilis. 2014. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-10-eng.php>. Date accessed: Dec 6, 2017.
16. Braun DL, Marzel A, Steffens D, *et al.* High rates of subsequent asymptomatic STIs and risky sexual behavior in patients initially presenting with primary HIV-1 infection. *Clin Infect Dis* Published Online First: 5 October 2017. doi:10.1093/cid/cix873
17. Cohen CE, Winston A, Asboe D, *et al.* Increasing detection of asymptomatic syphilis in HIV patients. *Sex Transm Infect* 2005;**81**:217-219.

- 1  
2  
3 18. Rompalo AM, Cannon RO, Quinn TC, *et al.* Association of biologic false-positive  
4 reactions for syphilis with human immunodeficiency virus infection. *J Infect Dis* 1992;  
5  
6 **165**:1124–2  
7  
8  
9  
10 19. Buchacz K, Patel P, Taylor M, *et al.* Syphilis increases HIV viral load and decreases CD4  
11 cell counts in HIV-infected patients with new syphilis infections. *AIDS*  
12  
13 2004;**18**(15):2075–9.  
14  
15  
16 20. Palacios R, Jimenez-Onate F, Aguilar M, *et al.* Impact of syphilis infection on HIV viral  
17 load and CD4 cell counts in HIV-infected patients. *J Acquir Immune Defic Syndr* 2007;  
18  
19 **44**(3):356–9.  
20  
21  
22  
23 21. Sadiq ST, McSorley J, Copas AJ, *et al.* The effects of early syphilis on CD4 counts and  
24 HIV-1 RNA viral loads in blood and semen. *Sex Transm Infect* 2005;**81**:380–5.  
25  
26  
27 22. Rolfs RT, Joesoef MR, Hendershot EF, *et al.* A randomized trial of enhanced therapy for  
28 early syphilis in patients with and without human immunodeficiency virus infection. The  
29 Syphilis and HIV Study Group, *N Engl J Med* 1997;**337**:307-15.  
30  
31  
32  
33 23. Workowski KA, Berman SM. Centers for Disease C, Prevention. Sexually transmitted  
34 diseases treatment guidelines. *MMWR Recomm Rep* 2010;**59**(12):1-110.  
35  
36  
37 24. Libois A, De Wit S, Poll B, *et al.* HIV and syphilis: when to perform a lumbar puncture.  
38 *Sex Transm Dis* 2007;**34**(3):141-4  
39  
40  
41  
42 25. Marra CM, Maxwell CL, Smith SL, *et al.* Cerebrospinal fluid abnormalities in patients  
43 with syphilis: association with clinical and laboratory features. *J Infect Dis*  
44  
45 2004;**189**:369-76.  
46  
47  
48  
49 26. Ghanem KG, Moore RD, Rompalo AM, *et al.* Neurosyphilis in a clinical cohort of HIV 1  
50 infected patients. *AIDS* 2008;**22**(10):1145-51.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Percentage of Syphilis Episodes Divided by Symptoms at time of Positive Syphilis Testing




Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected population.

127x71mm (300 x 300 DPI)






Figure 2: Percentage of syphilis episodes divided by symptom at presentation based on initial RPR titer. Individuals who had symptoms compared to those that did not were more likely to have a higher initial RPR ( $P=0.0339$ ). The most common symptoms were rash and ulcer/lesion with flu-like illness, condylomata and lymphadenopathy being relatively rare. Those with neurologic symptoms had a significant elevation of their initial RPR titers compared with all other symptoms ( $P<0.001$ ) and there were no cases of neurosyphilis with RPR titers less than 1:32 dilutions.

71x40mm (600 x 600 DPI)




Figure 3: There is an increased number of incident syphilis infections among HIV positive individuals who are active in care programs from 2006-2016. There is an apparent trend of decreased proportion of late latent disease.

71x40mm (300 x 300 DPI)




Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2 cells/mm<sup>3</sup> (P =0.004).

127x127mm (300 x 300 DPI)




Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis co-infection (P =0.47).

127x127mm (300 x 300 DPI)




Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by recurrent infections. There is a trend demonstrating that individuals with recurrent syphilis infections were more likely to be symptomatic on presentation, however this did not reach significance ( $P=0.0799$ ).

71x40mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b> Page 1,2	1	(a) Indicate the study's design with a commonly used term in the title or the abstract  (b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>		
Background/rationale Page 4	2	Explain the scientific background and rationale for the investigation being reported
Objectives Page 5	3	State specific objectives, including any prespecified hypotheses
<b>Methods</b>		
Study design Page 5	4	Present key elements of study design early in the paper
Setting Page 6	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants Page 5	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants  (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables Page 5,6, 7	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement Page 6,7	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias Page 7	9	Describe any efforts to address potential sources of bias
Study size Page 8	10	Explain how the study size was arrived at
Quantitative variables Page 7	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods Page 7	12	(a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy  (e) Describe any sensitivity analyses

Continued on next page

**Results**

Participants Page 8	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data Page 8,9	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data Page 8	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results Page 10, 11, 12	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses Page 12, 13	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

**Discussion**

Key results Page 13, 14, 15	18	Summarise key results with reference to study objectives
Limitations Page 3	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation Page 16	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability Page 3	21	Discuss the generalisability (external validity) of the study results

**Other information**

Funding Page 18	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
--------------------	----	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## A retrospective study of the clinical features of new syphilis infections in a HIV positive cohort in Alberta, Canada.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021544.R1
Article Type:	Research
Date Submitted by the Author:	17-Mar-2018
Complete List of Authors:	Lang, Raynell; University of Calgary Cumming School of Medicine, Department of Medicine Read, Ron; University of Calgary Cumming School of Medicine, Department of Medicine Krentz, Hartmut ; Alberta Health Services, S. Alberta HIV Clinic Peng, Mingkai; University of Calgary, Department of Community Health Sciences Ramazani, Soheil; Alberta Health Services, S. Alberta HIV Clinic Vu, Quang; Alberta Health Services, S. Alberta HIV Clinic Gill, M John; University of Calgary Cumming School of Medicine, Department of Medicine; Alberta Health Services, S. Alberta HIV Clinic
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Sexual health, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts





1  
2  
3 1 **TITLE:** A RETROSPECTIVE STUDY OF THE CLINICAL FEATURES OF NEW SYPHILIS  
4  
5 2 INFECTIONS IN A HIV POSITIVE COHORT IN ALBERTA, CANADA.  
6  
7 3

8 4 **AUTHORS:**  
9

10 5 Raynell Lang, Department of Medicine, University of Calgary, Calgary, Canada  
11

12 6 Ron Read, Department of Medicine, University of Calgary, Calgary STI Clinic Calgary, Canada.  
13

14 7 Hartmut B. Krentz, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
15

16 8 Mingkai Peng, Department of Community Health Sciences, University of Calgary, Calgary.  
17

18 9 Canada.  
19

20 10 Soheil Ramazani, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
21

22 11 Quang Vu, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
23

24 12 M. John Gill, Department of Medicine, University of Calgary, S Alberta HIV Clinic, Alberta  
25

26 13 Health Services, Calgary, Canada.  
27  
28  
29  
30  
31  
32

33 15 **CORRESPONDING AUTHOR:** M John Gill Department of Medicine 3330 Hospital drive  
34

35 16 NW Calgary Alberta T2N4N1 Telephone: 403 955 6315 Fax: 403 955 6333  
36

37 17 Email: John.Gill@albertahealthservices.ca  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** Syphilis is a global health concern with an estimated twelve million infections occurring annually. Due to the increasing rates of new syphilis infections being reported in HIV-infected patients, and their higher risk for atypical and severe presentations, periodic screening has been recommended as a routine component of HIV care. We aimed to characterize incident syphilis presentation, serologic features and treatment response in a well-defined, HIV-infected population over 11 years.

**Methods:** Since 2006, as routine practice of both the Southern Alberta Clinic (SAC) and Calgary STI Programs (CSTI) syphilis screening has accompanied HIV viral load measures every four months. All records of patients who, while in HIV care, either converted from being syphilis seronegative to a confirmed seropositive or were re-infected as evidenced by a four-fold increase in rapid plasma reagin (RPR) after past successful treatment, were reviewed.

**Results:** We identified 249 incident syphilis infections in 194 different HIV-infected individuals; 72% were initial infections whereas 28% were reinfections. Half (50.8%) of the infections were asymptomatic and identified only by routine screening. Symptomatic syphilis was more common when rapid plasma reagin (RPR) titers were higher ( $P=0.03$ ). In patients with recurrent syphilis infection, a trend was noted favoring symptomatic presentation (62%,  $P=0.07$ ). All 10 patients with CNS syphilis involvement presented with an RPR titer  $\geq 1:32$ . Following syphilis infection a decline of 42 cells/mm<sup>3</sup> in CD4 ( $P=0.004$ ) was found, but no significant changes in viral load occurred. No association was found with the stage of syphilis or symptoms at presentation and ART use, CD4 count or virologic suppression.

1  
2  
3 1 **Conclusion:** Routine screening of our HIV-infected population identified many asymptomatic  
4  
5 2 syphilis infections. The interaction of HIV and syphilis infection appears to be bidirectional with  
6  
7 3 effects noted on both HIV and syphilis clinical and serological markers.  
8  
9  
10 4

## 11 12 5 **ARTICLE SUMMARY**

### 13 14 6 **Strengths and limitations of this study**

- 15  
16  
17 7 1. All HIV and STI care in our region is highly centralized and coordinated allowing for  
18  
19 8 detailed analyses of our population.
- 20  
21 9 2. Routine syphilis serology regardless of risk behaviors or symptomatology was obtained  
22  
23 10 every four months in our HIV-infected population, allowing close monitoring of clinical  
24  
25 11 characteristics, bidirectional interactions as well as inclusivity of incident syphilis  
26  
27 12 infections.
- 28  
29 13 3. The study population, while comprehensive and representing a Canadian perspective, is  
30  
31 14 from a single regional area and may not be representative of populations elsewhere that  
32  
33 15 have different rates of unprotected sexual activity and both prevalent HIV and syphilis  
34  
35 16 infections. In addition, access to care varies between centers and populations and our  
36  
37 17 rates and identification methods may not precisely match others.
- 38  
39 18 4. This study may underestimate the clinical impact of syphilis in an HIV-infected  
40  
41 19 population as patients not accessing care and individuals infected but lost to follow up or  
42  
43 20 moving out of Alberta were not analyzed.  
44  
45  
46  
47  
48  
49  
50 21  
51  
52 22  
53  
54 23  
55  
56  
57  
58  
59  
60

## INTRODUCTION:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Syphilis continues to be a major public health concern globally, with an estimated twelve million  
3 new infections annually[1]. HIV-infected individuals are eight times more likely to become  
4 infected with syphilis than the general population[2]. In 2016, in Alberta Canada, over 25% of all  
5 new syphilis infections occurred in men who have sex with men (MSM) co-infected with  
6 HIV[3]. It has been suggested that increased use of social media including websites and mobile  
7 apps targeted towards meeting sex partners as well as serosorting (finding sex partners with the  
8 same HIV serostatus for unprotected sex), may be contributing to the rebound of high risk sexual  
9 activity in this population[2, 4]. The suppression of HIV viral replication (viral load <1,000  
10 copies/mL) using antiretroviral therapy (ART) resulting in minimal risk for sexual transmission  
11 of HIV has received legal recognition in Canada[5]. As noted in a 2015 Swiss HIV Cohort study  
12 by Kouyos et al. there has been an accelerated rate of condomless sex since the recognition of  
13 HIV treatment as prevention. The reasons for increased risk behavior, particularly condomless  
14 sex are believed to be multifactorial, however in turn may be driving an increase in sexually  
15 transmitted infections (STIs)[6].

16  
17 Syphilis in HIV-infected patients can present in atypical or severe forms, such as ulcerative skin  
18 lesions, persistent chancres, gummatous disease, ocular disease and neurosyphilis[7-11]. One  
19 study showed that HIV-infected individuals have multiple chancres and are more likely to  
20 experience Jarisch-Herxheimer reactions (22% vs 12% respectively), and another showed that  
21 concomitant genital ulcers were more common in patients with secondary syphilis and HIV[7,  
22 8]. STIs may increase the risk of HIV acquisition via interruption of mucosal barriers and  
23 increased viral shedding[11-13]. It has also been suggested that ART may inadvertently increase

1 the incidence of syphilis by altering innate and acquired immune responses that may enhance  
2 susceptibility to syphilis infection[14]. Due to these increasing rates of syphilis and the higher  
3 likelihood of atypical and severe presentation, routine periodic screening (2-4 times annually) of  
4 HIV-infected persons has been recommended[4, 11, 15-17].

5  
6 The aim of this retrospective cohort study was both to characterize syphilis presentation,  
7 serologic features and treatment response in a large cohort of HIV-infected individuals engaged  
8 in HIV care and receiving regular syphilis testing, as well as to examine the effect of incident  
9 syphilis on HIV disease markers.

## 11 **METHODS**

### 12 **Study Population**

13 The Southern Alberta Clinic (SAC) and Calgary STI Clinic (CSTI) provide exclusive care to  
14 HIV-infected individuals living in southern Alberta, Canada. In a quality assurance project  
15 (approved by University of Calgary Bioethics committee) at both programs between January 1,  
16 2006 and December 31, 2016, routine syphilis serology regardless of risk was ordered every four  
17 months accompanying HIV viral load testing. The records of all incident syphilis infections  
18 occurring in HIV-infected patients were reviewed. Every indeterminate or positive syphilis  
19 serology for a SAC patient was discussed with or referred to CSTI at the time of testing.

20  
21 All individuals with at least one visit between January 1, 2006 and December 31, 2016 were  
22 studied. Patients were followed until December 31, 2016 or until they moved, died or were lost-  
23 to-follow-up. All patients, who while in HIV care, converted from being seronegative for

1 syphilis to a confirmed positive status or were re-infected with syphilis were reviewed through  
2 the SAC database and a CSTI chart review.

### 3 4 **Diagnosis**

5 The syphilis screening algorithm and confirmatory testing was achieved using indirect serologic  
6 methods. Initially screening for syphilis was done with the non-treponemal rapid plasma reagin  
7 (RPR), however in 2008 the screening test was changed to an enzyme immunoassay (EIA), a  
8 treponemal test. The RPR continued to be used as a confirmatory test as well as for monitoring  
9 response to therapy[15, 18]. In Calgary, the secondary confirmatory test was either the  
10 fluorescent treponemal antibody absorption test (FTA-ABS) or the line immunoassay (INNO-  
11 LIA)[19].

12  
13 Recurrent syphilis episodes were identified by a four-fold increase in RPR after a prior  
14 documented successful treatment course for syphilis and were evaluated and staged by an STI  
15 specialist (RR). Neurosyphilis was documented by a positive CSF-VRDL (Venereal disease  
16 research laboratory) on lumbar puncture as well as evaluated by an STI specialist (RR). HIV  
17 PrEP use was not extensively used in the community during the study period and any potential  
18 role seemed unlikely.

### 19 20 **Data Collection**

21 Detailed standardized information was collected by one physician (RL), through a  
22 comprehensive review of both SAC and CSTI charts and databases. Multiple data sources in

1 these records were accessed including nursing interviews, social work reports, self-administered  
2 questionnaires, laboratory reports, and physician notes.

3  
4 From the SAC database, we identified the number of syphilis tests performed yearly at the clinic  
5 per patient as well as the interval between tests. Demographic data was collected at the time of  
6 HIV diagnosis and incorporated into the SAC database. These data included: gender (i.e. male,  
7 female, transgendered), self-reported ethnicity (i.e. Caucasian, Indigenous,  
8 African/Caribbean/Black (ACB), Other) and most likely HIV exposure risk (i.e. MSM, HET-  
9 heterosexual sex, PWID (persons who inject drugs), and other).

10  
11 The stage of syphilis (i.e. primary, secondary, early latent, late latent) and symptomatology at  
12 presentation (i.e. rash, ulcer/lesion, flu-like illness, condylomata, lymphadenopathy, neurological  
13 (tinnitus/ocular), asymptomatic, other) were collected via review of CSTI charts. All episodes of  
14 syphilis were staged by an STI specialist (RR) based on both clinical and laboratory  
15 investigations. In the absence of symptoms, the staging of primary versus latent syphilis was  
16 based on the timing of rising RPR titers in relation to most recent prior titer. Prior history of  
17 comorbid infections including *Neisseria gonorrhoeae* and *Chlamydia trachomatis* were self-  
18 reported at the time of syphilis diagnosis.

19  
20 The initial RPR was documented at the time of syphilis diagnosis and recorded in CSTI charts.  
21 HIV viral load and CD4 counts were measured at the time of syphilis diagnosis and subsequently  
22 at the next routine HIV follow-up appointment. HIV viral suppression was defined as a plasma  
23 viral load <40 copies/mL. Treatment modalities (i.e. Benzathine Penicillin, Doxycycline,

1 Penicillin G) and response to therapy were reviewed retrospectively through a comprehensive  
2 chart review. All data was anonymized prior to analysis.

### 3 4 **Patient and Public Involvement**

5 Routine testing for syphilis was introduced as standard care initiative. Patients were made aware  
6 of the new testing when given their routine HIV laboratory test requisitions and advised they  
7 have the option to delete the test if they wish. After identifying the large number of incident  
8 syphilis cases with half being asymptomatic we incorporated our local findings into our routine  
9 patient safer sex counselling. Our findings have been provided to local public health and will be  
10 used in broader STI control initiatives.

### 11 12 **Statistical Analysis**

13 Demographic and clinical factors of patients were compared using chi-square test. Viral load and  
14 CD4 counts prior to and following episode of syphilis infection were compared using linear  
15 mixed effect model while accounting for repeated measurement and more than one episode for  
16 some patients. Subgroup analyses were performed on neurosyphilis infections and those with  
17 recurrent episodes of syphilis. Patients not accessing care and individuals infected but lost to  
18 follow up or moving out of Alberta were not analyzed. All statistical analysis was performed  
19 using R (R Development Core Team, 2005). All charts were created with Microsoft Excel and R.

## 20 21 **RESULTS:**

### 22 **Demographics**



1  
2  
3 1 Between 2006 and 2016, there were 20,203 syphilis tests done on a total of 2,448 patients who  
4  
5 2 attended at least one regular SAC visit during that time. On average, there were 180 days  
6  
7 3 between each syphilis test per patient. The average number of syphilis screening tests that were  
8  
9 4 done per patient each year over the 11-year period was 2.1. In 2006, the average number of tests  
10  
11 5 per year was 1.3, whereas in 2016 this was 2.8. For high risk patients (MSM), screening rates  
12  
13 6 were more frequent with the average testing over 11 years being 2.4 tests per year.  
14  
15  
16  
17  
18

19 8 Of the 2,448 HIV-infected individuals at SAC and CSTI programs encompassing 15,175 person  
20  
21 9 years of follow up between 1/1/2006 and 12/31/2016, we identified 322 incident syphilis  
22  
23 10 infections, occurring in 267 different patients. There were 73 syphilis episodes in 73 patients that  
24  
25 11 were excluded. Of those excluded; 41 patients, while being tested in Alberta, had moved out of  
26  
27 12 province resulting in incomplete clinical data, and in 32 patients, there was inadequate basic  
28  
29 13 information available for study inclusion. We therefore analyzed 249 episodes in 194  
30  
31 14 individuals.  
32  
33  
34  
35  
36  
37

38 16 Of the 249 infections, 178 (72%) were first episode of a syphilis infection, whereas the  
39  
40 17 remaining 71 (28%) were recurrent episodes. The annual incidence rates of syphilis in our HIV-  
41  
42 18 infected population tripled from 2011, 8.08/1000 patient-years (95% confidence interval (CI):  
43  
44 19 4.14-14.75), to 27.04 per 1000 person-years (95% confidence interval (CI): 19.45-36.76) in  
45  
46 20 2016[3]. Prior history of STI's included; 32% of cases having a self-reported history of *Neisseria*  
47  
48 21 *gonorrhoeae* and 24% having had *Chlamydia trachomatis* infection. The characteristics of the  
49  
50 22 194 individuals included in this analysis are described in table 1.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: Characteristics of HIV+ patients regularly followed at the Southern Alberta Clinic between 1/1/2006 and 12/31/2016 comparing patients who were negative for syphilis (Syphilis Neg) to patients who ever tested positive for syphilis (Syphilis Pos).**

	Syphilis Neg	Syphilis Pos	P-value
N (%)	2254 (92.1)	194 (7.9)	
<b>Age at HIV Diagnosis (years)</b>			
Mean (range)	35 (1-79)	35 (16-69)	0.893
<30	813 (36.1)	75 (38.7)	0.801
30-39	802 (35.6)	66 (34.0)	
40-49	438 (19.4)	37 (19.1)	
≥50	201 (8.9)	16 (8.3)	
<b>Gender</b>			
Male	1675 (74.3)	183 (94.3)	<.001
Female	572 (25.4)	11 (5.6)	
Transgendered	7 (0.3)	0 (0.0)	
<b>Self-reported Ethnicity<sup>1</sup></b>			
Caucasian	1259 (56.0)	140 (72.2)	<.001
Indigenous	216 (9.6)	6 (3.1)	
ACB	536 (23.8)	24 (12.4)	
Other	243 (10.8)	24 (12.4)	
<b>Most Likely HIV Exposure Category<sup>2</sup></b>			
MSM	915 (40.6)	145 (74.4)	<.001
HET	512 (22.7)	14 (7.2)	
PWID	731 (32.4)	30 (15.6)	
Other	96 (4.3)	5 (2.6)	

<sup>1</sup>Indigenous people includes Aboriginal, Metis and Inuit; ACB includes African, Caribbean, Black; Other includes IndoAsian, Hispanic, East Asian, and other

<sup>2</sup>MSM=self-reported men who have sex with men identification; HET=self-reported heterosexual identification; PWID=self-reported intravenous drug use identification; Other HIV Risk factor behavior includes: blood transfusions, hemophiliac, neonatal, postnatal infection, unknown or not reported.

### Symptomatology

#### Asymptomatic syphilis episodes

Just over half of the episodes (50.8%) of incident syphilis infections were asymptomatic and identified by routine screening (Figure 1). RPR titers were higher in patients with symptomatic versus asymptomatic syphilis (P=0.03) (Figure 2). The majority of episodes with an initial RPR

1 of 1:4 or less were asymptomatic (71%). Those with lower CD4 ( $<200$  cells/mm<sup>3</sup>) counts at  
2 syphilis diagnosis had no significant differences in symptomatology as opposed to those with  
3 CD4 counts  $>200$  cells/mm<sup>3</sup> (P= 0.65). Neither virologic suppression of HIV nor ART use  
4 influenced the individual's likelihood to present with symptomatic syphilis.

### 6 *Symptomatic syphilis episodes*

7 The most common presenting symptom was rash (23%), followed by skin lesion or ulceration  
8 (18%). Uncommon presentations included lymphadenopathy, flu-like illness, condylomata lata  
9 and neurological symptoms (Figure 1). The most common presenting symptom in primary  
10 syphilis was skin ulceration/lesion (57%) and in those with secondary syphilis was a rash (76%).  
11 However, 15% of those diagnosed with secondary syphilis also complained of skin ulceration or  
12 lesion in addition to a rash. Although rare overall as presenting symptoms, lymphadenopathy  
13 (86%), flu like illness (50%) and condylomata (100%) were most seen in primary syphilis.

### 15 **Stage of Syphilis**

16 Both ART and virologic suppression of HIV had no association with the individual's stage of  
17 syphilis at diagnosis. Of those diagnosed with late latent syphilis, 98% had an initial RPR of 1:16  
18 or less. Patients with secondary syphilis tended to present with a higher RPR, 33% having an  
19 RPR of 1:256 or higher.

21 Since 2008, the proportion of late latent syphilis infections diagnosed among our HIV-infected  
22 patients in care had decreased from 44% to 4.4% (Figure 3). Caucasian individuals were more  
23 likely to present with primary (24%) or secondary (28%) syphilis (P= $<0.001$ ), whereas the non-

1 Caucasian population were more likely to present with latent disease (74%) ( $P=<0.001$ ). In  
2 males, the majority of infections were early latent (34%) and the minority being late latent  
3 (18%). However, in females 77% of infections were late latent.

#### 5 **Effect of Syphilis on Markers of HIV**

6 As the interaction of HIV and syphilis infection may be bidirectional we explored CD4 and viral  
7 load response to syphilis infection. A significant decrease in CD4 count of 42.2 cells/mm<sup>3</sup>  
8 ( $P=0.004$ ) was noted in association with syphilis coinfection (Figure 4). However, there was no  
9 change in HIV viral load noted in association with syphilis coinfection ( $P=0.47$ ) (Figure 5).

#### 11 **Effect of HIV on Markers of Syphilis**

12 Nearly half (49%) of all patients presented with RPR (non-treponemal) titers between 1:32-  
13 1:128. There were two episodes presenting with an initial RPR greater than 1:2048; both patients  
14 were not HIV virologically suppressed (HIV plasma viral load  $>1,000$  copies/mL) at the time of  
15 syphilis infection (Figure 2). The individuals viral load ( $P=0.82$ ) or CD4 count ( $P=0.48$ ) did not  
16 appear to have any correlation with the initial RPR titer. We were unable to evaluate if the  
17 absence of ART had an impact on RPR titer due to the small number of patients not on ART  
18 ( $n=48$ ).

#### 20 **Recurrent Episodes of Syphilis**

21 In patients with recurrent syphilis infection, a trend ( $P=0.07$ ) was noted favoring symptomatic  
22 presentation (62%). Rash and skin lesion/ulceration also remained the most common complaint  
23 (Figure 6). Recurrent episodes of syphilis were much less likely to be late latent disease (3%)

1 and instead more likely to be primary (28%), secondary (28%) or early latent disease (39%). Of  
2 those with a recurrent syphilis episode, 29% had RPR titers over 1:256, compared to 18% in the  
3 study population. Only 10% of the patients with prior syphilis exposure had an initial RPR less  
4 than 1:4 compared to 32% in the study population, however this did not reach significance  
5 (P=0.604).

## 6 7 **Neurosyphilis**

8 CNS involvement was noted in 10/249 (4%) episodes with a positive CSF-VDRL on lumbar  
9 puncture. Ocular symptoms with blurred vision or painless visual loss occurred in four patients,  
10 tinnitus in three patients and three were asymptomatic. Nine patients were male and Caucasian  
11 with eight being >40 years old. Eight were initial syphilis episodes and two were reinfections.  
12 Seven of the ten patients were on ART, five were virologically suppressed with seven having a  
13 CD4 count > 500 cells/mL. The RPR titer at diagnosis was  $\geq 1:32$  in all episodes of CNS  
14 involvement with five having an RPR titer of  $\geq 1:512$  and two of these episodes diagnosed with  
15 initial RPR titers of 1:8192. These RPR titers were much higher than any other symptom  
16 presentation (P=<0.001) (Figure 2). All patients with CNS involvement were treated  
17 successfully, based on both clinical and serologic response, with intravenous penicillin G for 14  
18 days.

## 19 20 **Treatment**

21 A standard three-week course of weekly intramuscular injections of Benzathine penicillin  
22 (2.4MU per dose) was used for 77% of the patients, while 10% received an oral course of  
23 doxycycline, and 10% received a combination of the two medications. Successful completion of

1 the full course of treatment was achieved in 94% (with 5% requiring retreatment from inadequate  
2 initial adherence and 1% never completing their full course).

### 4 **DISCUSSION:**

5 Our introduction in 2006 of syphilis screening to accompany routine HIV viral load testing  
6 allowed for the identification and analysis of incident syphilis infections in the HIV population in  
7 care in Calgary, Alberta. Our results confirm prior findings that co-infection with HIV can result  
8 in atypical or severe syphilis presentations[8-11]. Compared to non HIV-infected populations,  
9 prior studies have found higher rates of asymptomatic primary syphilis, which may result in  
10 missed diagnosis and increased episodes of secondary syphilis[11, 20]. In our study population,  
11 50.8% (135) syphilis episodes were asymptomatic at presentation, including 21% (10) of the  
12 primary syphilis infections. Braun et al. recently published a study evaluating symptoms of  
13 syphilis in 19 HIV-infected individuals and found the rate of asymptomatic syphilis infections in  
14 HIV-infected individuals to be 40%[21]. Routine syphilis screening has been confirmed to be  
15 effective in detecting early asymptomatic syphilis in HIV-infected outpatients[20].

16  
17 Our study demonstrated a decline in latent syphilis between 2008 (44%) and 2016 (4%). In 2008,  
18 the high numbers of latent syphilis may be reflective of a change to the testing algorithm for  
19 syphilis, from an initial RPR to enzyme immunoassay (EIA), resulting in an improved test  
20 sensitivity and the identification of latent syphilis[18, 19]. While latent episodes have been  
21 steadily declining since 2013, the number of primary syphilis diagnoses are increasing. Through  
22 regular syphilis screening in this HIV-infected population, earlier detection of syphilis in its

1 primary stage has been achieved, leading to prompt therapy, which may decrease ongoing  
2 syphilis transmission[4].

3  
4  
5  
6  
7  
8  
9  
10 The interaction of HIV and syphilis infection appears to be bidirectional with effects noted on  
11 both HIV and syphilis serologic and clinical markers[11]. Prior studies have reported that  
12 syphilis infection may increase HIV viral load and decrease CD4 count[22-25]. We observed a  
13 statistically significant decrease in CD4 count associated with incident syphilis infections, but no  
14 change in viral load was noted. This difference in findings compared with past studies may in  
15 part, be explained by the majority of our patients being on ART, which are perhaps more potent  
16 in suppressing viral replication.

17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28 An increased prevalence of neurologic manifestations has been reported in HIV-infected  
29 individuals[2, 4]. Approximately one third of any patient with early syphilis will have  
30 treponemal invasion into their CNS regardless of their HIV status[4]. However, an increased rate  
31 of early neurosyphilis among HIV-infected individuals has been noted and may be linked to the  
32 patient's inability to control the CNS infection rather than increased invasion into the CNS[4,  
33 25]. Our data revealed 10/249 (4%) of the syphilis episodes diagnosed in our HIV-infected  
34 cohort were neurosyphilis.

35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47 Neurosyphilis is more likely to be asymptomatic in HIV co-infected individuals and therefore a  
48 more difficult diagnosis[4]. Three of our ten neurosyphilis episodes were indeed asymptomatic.  
49 As a response to the absence of symptoms, CDC guidelines recommend HIV-infected  
50 individuals who receive a diagnosis of late latent syphilis, unknown duration of disease, have  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 neurologic symptoms or treatment failure should undergo CSF evaluation[4, 26]. It is  
2 controversial whether all HIV co-infected individuals require evaluation for neurosyphilis at the  
3 time of syphilis diagnosis[4].

4  
5 Recent data suggests that there is an association with RPR titers  $\geq 1:32$  and laboratory defined  
6 neurosyphilis (sensitivity of 100%, specificity of 40%)[24, 25]. This is in keeping with our study  
7 findings, deducing that lumbar puncture could be restricted to the subgroup of patients with  
8 neurologic manifestation or a serum RPR of  $\geq 1:32$ [27, 28]. Prior studies have found that patients  
9 with CD4 counts  $< 350\text{mm}^3$ , may be at increased risk for neurosyphilis, however we identified no  
10 specific correlation[4, 28, 29]. We did note that five of the individuals with neurosyphilis were  
11 not HIV virologically suppressed, suggesting that there may be a link between increased HIV  
12 viral loads and neurosyphilis, however this requires further study.

### 13 14 **CONCLUSIONS:**

15 Through routine screening of an HIV-infected population engaged in care, many asymptomatic  
16 syphilis episodes were identified and treated resulting in a shift in diagnostic stage of syphilis  
17 infection from latent to primary and a theoretical decrease in ongoing transmission. Individuals  
18 with symptomatic syphilis infections were more likely to have higher RPR titers and those with  
19 highest RPR titers were at greater risk of having neurosyphilis. ART, CD4 count and virologic  
20 suppression of HIV had no association with the individual's stage of syphilis or symptoms at  
21 diagnosis. Syphilis infection was associated with a temporary decrease in CD4 count with no  
22 impact on HIV viral load. As the rates of syphilis rise among the HIV-infected population,



1 ongoing vigilance in screening and treatment is required in addition to further examination of co-  
2 infection interactions.

#### 3 4 5 6 7 8 9 10 **KEY MESSAGES**

- 11 1. Through routine syphilis testing of an HIV-infected population many asymptomatic  
12 syphilis episodes were detected and treated.
- 13 2. Symptomatic individuals at diagnosis were more likely to have higher RPR titers.
- 14 3. Syphilis coinfection was associated with a temporary decrease in CD4 count, but no  
15 change in viral load was noted.
- 16 4. Patients with neurosyphilis were more likely to have higher RPR titers at diagnosis with  
17 no cases occurring in patients with titers <1:32.

#### 18 19 20 21 22 23 24 25 26 27 28 29 30 **FIGURE LEGENDS:**

31  
32  
33 Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected  
34 population.

35  
36  
37  
38 Figure 2: Percentage of syphilis episodes divided by symptom at presentation based on initial  
39 RPR titer. Individuals who had symptoms compared to those that did not were more likely to  
40 have a higher initial RPR ( $P=0.0339$ ). The most common symptoms were rash and ulcer/lesion  
41 with flu-like illness, condylomata and lymphadenopathy being relatively rare. Those with  
42 neurologic symptoms had a significant elevation of their initial RPR titers compared with all  
43 other symptoms ( $P=<0.001$ ) and there were no cases of neurosyphilis with RPR titers less than  
44 1:32 dilutions.

1  
2  
3 1 Figure 3: There is an increased number of incident syphilis infections among HIV positive  
4  
5 2 individuals who are active in care programs from 2006-2016. There is an apparent trend of  
6  
7 3 decreased proportion of late latent disease.  
8  
9

10  
11 4 Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up  
12  
13 5 appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2  
14  
15 6 cells/mm<sup>3</sup> (P =0.004).  
16  
17

18  
19 7 Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation  
20  
21 8 in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of  
22  
23 9 syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis  
24  
25 10 co-infection (P =0.47).  
26  
27

28  
29 11 Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by  
30  
31 12 recurrent infections. There is a trend demonstrating that individuals with recurrent syphilis  
32  
33 13 infections were more likely to be symptomatic on presentation, however this did not reach  
34  
35 14 significance (P=0.0799).  
36  
37

38  
39 15

## 16 **DECLARATIONS:**

17 **Ethics approval and consent to participate:** Ethics approval was obtained through the  
18 University of Calgary Bioethics committee as a quality assurance project through A Project  
19 Ethics Community Consensus Initiative (ARECCI). Approval was granted both verbally and  
20 written on Aug 23, 2016.  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 **Data sharing:** The datasets generated and/or analyzed during the current study are not publicly  
4  
5 2 available due to patient confidentiality. The sensitive nature of this information as well as the  
6  
7 3 relatively small number of patients included in this dataset may lead it to be identifying and  
8  
9 4 therefore does not allow this dataset to be made public.

10  
11  
12  
13 5 **Funding:** No funding was received for this work.

14  
15  
16  
17 6 **Conflicts of interest:** We have no relevant conflicts of interest to disclose.

18  
19  
20 7 This work was previously presented at ID week 2017 in San Diego, California.

21  
22  
23  
24 8 **Authors' contributions:** RL, RR, HK and JG were involved in study design, data extraction,  
25  
26 9 data analysis, drafting and final review of this work. SR, MP, and QV were involved in data  
27  
28 10 extraction, data analysis and final review of this work. All authors read and approved the final  
29  
30 11 manuscript.

31  
32  
33  
34 12 **Acknowledgments:** We would like to thank all clinic staff at SAC and CSTI and especially  
35  
36 13 Janet Furseth and Jennifer Gratrix for their help in the project.

37  
38  
39  
40 14

41  
42  
43 15 **REFERENCES:**

- 44  
45 16 1. World Health Organization, Dept of Reproductive Health and Research. Global incidence  
46  
47 17 and prevalence of selected curable sexually transmitted infections – 2008. 2012.  
48  
49 18 Available at: <http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/>.  
50  
51 19 Date accessed: Dec 6, 2017.

- 1  
2  
3 1 2. Karp G, Schleffer F, Jotkowitz A, *et al.* Syphilis and HIV co-infection. *Eur. J. Intern.*  
4  
5 2  
6 *Med* 2009;**20**:9-13.
- 7  
8 3  
9 3. Lang R, Read R, Krentz HB, *et al.* Increasing incidence of syphilis among patients  
10 4  
11 engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. *BMC*  
12 5  
13 *Infect Dis* 2018;**18**:125.
- 14 6  
15 4. Zetola NM, Klausner JD. Syphilis and HIV Infection: An Update. *CID* 2007;**44**:1222-8.
- 16 7  
17 5. R. v. Mabior, 2012 SCC 47, [2012] 2 S.C.R. 584. Available at: <https://scc->  
18  
19 8  
20 [csc.lexum.com/scc-csc/scc-csc/en/item/10008/index.do](https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/10008/index.do). Date accessed: Dec 1, 2017.
- 21 9  
22 6. Kouyos RD, Hasse B, Calmy A, *et al.* Increases in Condomless Sex in the Swiss HIV  
23  
24 10  
25 Cohort Study. *Open Forum Infect Dis* 2015;**2**(2):ofv077.
- 26 11  
27 7. Rolfs RT, Joesoef MR, Hendershot EF, *et al.* A randomized trial of enhanced therapy for  
28 12  
29 early syphilis in patients with and without human immunodeficiency virus infection. The  
30  
31 13  
32 Syphilis and HIV Study Group, *N Engl J Med* 1997;**337**:307-15.
- 33 14  
34 8. Rompalo AM, Joesoef MR, O'Donnell JA, *et al.* Clinical Manifestations of Early  
35 15  
36 Syphilis by HIV Status and Gender: Results of the Syphilis and HIV Study. *Sex Transm*  
37 16  
38 *Dis* 2001;**28**(3):158-65.
- 39 17  
40 9. Marra CM, Tantalo LC, Sahi SK, *et al.* Reduced Treponema pallidum-Specific Opsonic  
41  
42 18  
43 Antibody Activity in HIV-Infected Patients with Syphilis. *J Infect Dis* 2016;**213**:1348-54.
- 44 19  
45 10. Collis TK, Celum CL. The Clinical Manifestations and treatment of Sexually Transmitted  
46  
47 20  
48 Diseases in Human Immunodeficiency Virus-Positive Men. *Clin Infect Dis* 2001;**32**:611-  
49 21  
50 22.
- 51 22  
52 11. Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. *Lancet Infect Dis*  
53  
54 23  
55 2004;**4**:456-66.

- 1  
2  
3 1 12. McCoy SI, Eron JJ, Kuruc JD, *et al.* Sexually transmitted infections among patients with  
4 acute HIV in North Carolina. *Sex Transm Dis* 2009;**36**(6):372–4.  
5  
6 2  
7  
8 3 13. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and  
9 practice: the contribution of other sexually transmitted diseases to sexual transmission of  
10 HIV infection. *Sex Transm Infect* 1999;**75**:3–17.  
11  
12 4  
13 5  
14 6 14. Rekart ML, Ndifon W, Brunham RC, *et al.* A double-edged sword: does highly active  
15 antiretroviral therapy contribute to syphilis incidence by impairing immunity to  
16 *Treponema pallidum*? *Sex Transm Infect* 2017;**0**:1-5.  
17 7  
18 8  
19 9 15. Branger J, Van Der Meer JT, Van Ketel RJ, *et al.* High Incidence of Asymptomatic  
20 Syphilis in HIV-Infected MSM Justifies Routine Screening. *Sex Transm Dis*  
21 2009;**36**(2):84-5.  
22 10  
23 11  
24 12 16. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment  
25 Guidelines, 2015. Available at: <https://www.cdc.gov/std/tg2015/tg-2015-print.pdf>. Date  
26 accessed: Feb 26, 2017.  
27 13  
28 14  
29 15 17. European AIDS Clinical Society (EACS). Guidelines Version 9.0. 2017. Available at:  
30 [http://www.eacsociety.org/files/guidelines\\_9.0-english.pdf](http://www.eacsociety.org/files/guidelines_9.0-english.pdf). Date accessed Feb 26, 2017.  
31 16  
32 17  
33 18 18. Ratnam S. The laboratory diagnosis of syphilis. *Can J Infect Dis Med Microbiol*  
34 2005;**16**(1):45-51.  
35 19  
36 20 19. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted  
37 Infections: Syphilis. 2014. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-10-eng.php>. Date accessed: Dec 6, 2017.  
38 21  
39 22  
40 23 20. Cohen CE, Winston A, Asboe D, *et al.* Increasing detection of asymptomatic syphilis in  
41 HIV patients. *Sex Transm Infect* 2005;**81**:217-219.  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 1 21. Braun DL, Marzel A, Steffens D, *et al*. High rates of subsequent asymptomatic STIs  
4 and risky sexual behavior in patients initially presenting with primary HIV-1 infection.  
5  
6 2  
7  
8 3  
9  
10 4 22. Buchacz K, Patel P, Taylor M, *et al*. Syphilis increases HIV viral load and decreases CD4  
11 cell counts in HIV-infected patients with new syphilis infections. *AIDS*  
12  
13 5  
14 6  
15 2004;**18**(15):2075–9.  
16  
17 7 23. Palacios R, Jimenez-Onate F, Aguilar M, *et al*. Impact of syphilis infection on HIV viral  
18 load and CD4 cell counts in HIV-infected patients. *J Acquir Immune Defic Syndr* 2007;  
19 8  
20  
21 9  
22 44(3):356–9.  
23  
24 10 24. Sadiq ST, McSorley J, Copas AJ, *et al*. The effects of early syphilis on CD4 counts and  
25 HIV-1 RNA viral loads in blood and semen. *Sex Transm Infect* 2005;**81**:380–5.  
26 11  
27  
28 12 25. Rolfs RT, Joesoef MR, Hendershot EF, *et al*. A randomized trial of enhanced therapy for  
29 early syphilis in patients with and without human immunodeficiency virus infection. The  
30  
31 13  
32 Syphilis and HIV Study Group, *N Engl J Med* 1997;**337**:307-15.  
33 14  
34  
35 15 26. Workowski KA, Berman SM. Centers for Disease C, Prevention. Sexually transmitted  
36 diseases treatment guidelines. *MMWR Recomm Rep* 2010;**59**(12):1-110.  
37 16  
38  
39 17 27. Libois A, De Wit S, Poll B, *et al*. HIV and syphilis: when to perform a lumbar puncture.  
40  
41 18  
42 2007;**34**(3):141-4  
43  
44 19 28. Marra CM, Maxwell CL, Smith SL, *et al*. Cerebrospinal fluid abnormalities in patients  
45 with syphilis: association with clinical and laboratory features. *J Infect Dis*  
46  
47 20  
48 2004;**189**:369-76.  
49 21  
50  
51 22 29. Ghanem KG, Moore RD, Rompalo AM, *et al*. Neurosyphilis in a clinical cohort of HIV 1  
52 infected patients. *AIDS* 2008;**22**(10):1145-51.  
53  
54 23  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1

For peer review only

Percentage of Syphilis Episodes Divided by Symptoms at time of Positive Syphilis Testing




Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected population.

127x71mm (300 x 300 DPI)






Figure 2: Percentage of syphilis episodes divided by symptom at presentation based on initial RPR titer. Individuals who had symptoms compared to those that did not were more likely to have a higher initial RPR ( $P=0.0339$ ). The most common symptoms were rash and ulcer/lesion with flu-like illness, condylomata and lymphadenopathy being relatively rare. Those with neurologic symptoms had a significant elevation of their initial RPR titers compared with all other symptoms ( $P<0.001$ ) and there were no cases of neurosyphilis with RPR titers less than 1:32 dilutions.

71x40mm (600 x 600 DPI)




Figure 3: There is an increased number of incident syphilis infections among HIV positive individuals who are active in care programs from 2006-2016. There is an apparent trend of decreased proportion of late latent disease.

71x40mm (300 x 300 DPI)




Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2 cells/mm<sup>3</sup> (P =0.004).

127x127mm (300 x 300 DPI)




Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis co-infection (P =0.47).

127x127mm (300 x 300 DPI)




Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by recurrent infections. There is a trend demonstrating that individuals with recurrent syphilis infections were more likely to be symptomatic on presentation, however this did not reach significance ( $P=0.0799$ ).

71x40mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b> Page 1,2	1	(a) Indicate the study's design with a commonly used term in the title or the abstract  (b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>		
Background/rationale Page 4	2	Explain the scientific background and rationale for the investigation being reported
Objectives Page 5	3	State specific objectives, including any prespecified hypotheses
<b>Methods</b>		
Study design Page 5	4	Present key elements of study design early in the paper
Setting Page 6	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants Page 5	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants  (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables Page 5,6, 7	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement Page 6,7	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias Page 7	9	Describe any efforts to address potential sources of bias
Study size Page 8	10	Explain how the study size was arrived at
Quantitative variables Page 7	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods Page 7	12	(a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy  (e) Describe any sensitivity analyses

Continued on next page

**Results**

Participants Page 8	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data Page 8,9	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data Page 8	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results Page 10, 11, 12	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses Page 12, 13	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

**Discussion**

Key results Page 13, 14, 15	18	Summarise key results with reference to study objectives
Limitations Page 3	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation Page 16	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability Page 3	21	Discuss the generalisability (external validity) of the study results

**Other information**

Funding Page 18	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
--------------------	----	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

# BMJ Open

## A retrospective study of the clinical features of new syphilis infections in a HIV positive cohort in Alberta, Canada.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-021544.R2
Article Type:	Research
Date Submitted by the Author:	25-Apr-2018
Complete List of Authors:	Lang, Raynell; University of Calgary Cumming School of Medicine, Department of Medicine Read, Ron; University of Calgary Cumming School of Medicine, Department of Medicine Krentz, Hartmut ; Alberta Health Services, S. Alberta HIV Clinic Peng, Mingkai; University of Calgary, Department of Community Health Sciences Ramazani, Soheil; Alberta Health Services, S. Alberta HIV Clinic Vu, Quang; Alberta Health Services, S. Alberta HIV Clinic Gill, M John; University of Calgary Cumming School of Medicine, Department of Medicine; Alberta Health Services, S. Alberta HIV Clinic
<b>Primary Subject Heading</b>:	Infectious diseases
Secondary Subject Heading:	HIV/AIDS, Sexual health, Public health
Keywords:	HIV & AIDS < INFECTIOUS DISEASES, Epidemiology < INFECTIOUS DISEASES, Public health < INFECTIOUS DISEASES

SCHOLARONE™  
Manuscripts





1  
2  
3 1 **TITLE:** A RETROSPECTIVE STUDY OF THE CLINICAL FEATURES OF NEW SYPHILIS  
4 2 INFECTIONS IN A HIV POSITIVE COHORT IN ALBERTA, CANADA.  
5  
6  
7 3

8 4 **AUTHORS:**  
9

10 5 Raynell Lang, Department of Medicine, University of Calgary, Calgary, Canada  
11

12 6 Ron Read, Department of Medicine, University of Calgary, Calgary STI Clinic Calgary, Canada.  
13

14 7 Hartmut B. Krentz, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
15

16 8 Mingkai Peng, Department of Community Health Sciences, University of Calgary, Calgary.  
17

18 9 Canada.  
19

20 10 Soheil Ramazani, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
21

22 11 Quang Vu, S Alberta HIV Clinic, Alberta Health Services, Calgary, Canada.  
23

24 12 M. John Gill, Department of Medicine, University of Calgary, S Alberta HIV Clinic, Alberta  
25

26 13 Health Services, Calgary, Canada.  
27  
28  
29  
30  
31  
32

33 15 **CORRESPONDING AUTHOR:** M John Gill Department of Medicine 3330 Hospital drive  
34

35 16 NW Calgary Alberta T2N4N1 Telephone: 403 955 6315 Fax: 403 955 6333  
36

37 17 Email: John.Gill@albertahealthservices.ca  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** Syphilis is a global health concern with an estimated twelve million infections occurring annually. Due to the increasing rates of new syphilis infections being reported in HIV-infected patients, and their higher risk for atypical and severe presentations, periodic screening has been recommended as a routine component of HIV care. We aimed to characterize incident syphilis presentation, serologic features and treatment response in a well-defined, HIV-infected population over 11 years.

**Methods:** Since 2006, as routine practice of both the Southern Alberta Clinic (SAC) and Calgary STI Programs (CSTI) syphilis screening has accompanied HIV viral load measures every four months. All records of patients who, while in HIV care, either converted from being syphilis seronegative to a confirmed seropositive or were re-infected as evidenced by a four-fold increase in rapid plasma reagin (RPR) after past successful treatment, were reviewed.

**Results:** We identified 249 incident syphilis infections in 194 different HIV-infected individuals; 72% were initial infections whereas 28% were reinfections. Half (50.8%) of the infections were asymptomatic and identified only by routine screening. Symptomatic syphilis was more common when rapid plasma reagin (RPR) titers were higher ( $P=0.03$ ). In patients with recurrent syphilis infection, a trend was noted favoring symptomatic presentation (62%,  $P=0.07$ ). All 10 patients with CNS syphilis involvement presented with an RPR titer  $\geq 1:32$ . Following syphilis infection a decline of 42 cells/mm<sup>3</sup> in CD4 ( $P=0.004$ ) was found, but no significant changes in viral load occurred. No association was found with the stage of syphilis or symptoms at presentation and ART use, CD4 count or virologic suppression.

1  
2  
3 1 **Conclusion:** Routine screening of our HIV-infected population identified many asymptomatic  
4  
5 2 syphilis infections. The interaction of HIV and syphilis infection appears to be bidirectional with  
6  
7 3 effects noted on both HIV and syphilis clinical and serological markers.  
8  
9  
10 4

## 11 12 5 **ARTICLE SUMMARY**

### 13 14 6 **Strengths and limitations of this study**

- 15  
16  
17 7 1. All HIV and STI care in our region is highly centralized and coordinated allowing for  
18  
19 8 detailed analyses of our population.  
20  
21 9 2. Routine syphilis serology regardless of risk behaviors or symptomatology was obtained  
22  
23 10 every four months in our HIV-infected population, allowing close monitoring of clinical  
24  
25 11 characteristics, bidirectional interactions as well as inclusivity of incident syphilis  
26  
27 12 infections.  
28  
29 13 3. The study population, while comprehensive and representing a Canadian perspective, is  
30  
31 14 from a single regional area and may not be representative of populations elsewhere that  
32  
33 15 have different rates of unprotected sexual activity and both prevalent HIV and syphilis  
34  
35 16 infections. In addition, access to care varies between centers and populations and our  
36  
37 17 rates and identification methods may not precisely match others.  
38  
39 18 4. This study may underestimate the clinical impact of syphilis in an HIV-infected  
40  
41 19 population as patients not accessing care and individuals infected but lost to follow up or  
42  
43 20 moving out of Alberta were not analyzed.  
44  
45  
46  
47  
48  
49  
50 21  
51  
52 22  
53  
54 23  
55  
56  
57  
58  
59  
60

## INTRODUCTION:

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 Syphilis continues to be a major public health concern globally, with an estimated twelve million  
3 new infections annually[1]. HIV-infected individuals are eight times more likely to become  
4 infected with syphilis than the general population[2]. In 2016, in Alberta Canada, over 25% of all  
5 new syphilis infections occurred in men who have sex with men (MSM) co-infected with  
6 HIV[3]. It has been suggested that increased use of social media including websites and mobile  
7 apps targeted towards meeting sex partners as well as serosorting (finding sex partners with the  
8 same HIV serostatus for unprotected sex), may be contributing to the rebound of high risk sexual  
9 activity in this population[2, 4]. The suppression of HIV viral replication (viral load <1,000  
10 copies/mL) using antiretroviral therapy (ART) resulting in minimal risk for sexual transmission  
11 of HIV has received legal recognition in Canada[5]. As noted in a 2015 Swiss HIV Cohort study  
12 by Kouyos et al. there has been an accelerated rate of condomless sex since the recognition of  
13 HIV treatment as prevention. The reasons for increased risk behavior, particularly condomless  
14 sex are believed to be multifactorial, however in turn may be driving an increase in sexually  
15 transmitted infections (STIs)[6].

16  
17 Syphilis in HIV-infected patients can present in atypical or severe forms, such as ulcerative skin  
18 lesions, persistent chancres, gummatous disease, ocular disease and neurosyphilis[7-11]. One  
19 study showed that HIV-infected individuals have multiple chancres and are more likely to  
20 experience Jarisch-Herxheimer reactions (22% vs 12% respectively), and another showed that  
21 concomitant genital ulcers were more common in patients with secondary syphilis and HIV[7,  
22 8]. STIs may increase the risk of HIV acquisition via interruption of mucosal barriers and  
23 increased viral shedding[11-13]. It has also been suggested that ART may inadvertently increase

1 the incidence of syphilis by altering innate and acquired immune responses that may enhance  
2 susceptibility to syphilis infection[14]. Due to these increasing rates of syphilis and the higher  
3 likelihood of atypical and severe presentation, routine periodic screening (2-4 times annually) of  
4 HIV-infected persons has been recommended[4, 11, 15-17].

5  
6 The aim of this retrospective cohort study was both to characterize syphilis presentation,  
7 serologic features and treatment response in a large cohort of HIV-infected individuals engaged  
8 in HIV care and receiving regular syphilis testing, as well as to examine the effect of incident  
9 syphilis on HIV disease markers.

## 11 **METHODS**

### 12 **Study Population**

13 The Southern Alberta Clinic (SAC) and Calgary STI Clinic (CSTI) provide exclusive care to  
14 HIV-infected individuals living in southern Alberta, Canada. In a quality assurance project  
15 (approved by University of Calgary Bioethics committee) at both programs between January 1,  
16 2006 and December 31, 2016, routine syphilis serology regardless of risk was ordered every four  
17 months accompanying HIV viral load testing. The records of all incident syphilis infections  
18 occurring in HIV-infected patients were reviewed. Every indeterminate or positive syphilis  
19 serology for a SAC patient was discussed with or referred to CSTI at the time of testing.

20  
21 All individuals with at least one visit between January 1, 2006 and December 31, 2016 were  
22 studied. Patients were followed until December 31, 2016 or until they moved, died or were lost-  
23 to-follow-up. All patients, who while in HIV care, converted from being seronegative for

1 syphilis to a confirmed positive status or were re-infected with syphilis were reviewed through  
2 the SAC database and a CSTI chart review.

### 3 4 **Diagnosis**

5 The syphilis screening algorithm and confirmatory testing was achieved using indirect serologic  
6 methods. Initially screening for syphilis was done with the non-treponemal rapid plasma reagin  
7 (RPR), however in 2008 the screening test was changed to an enzyme immunoassay (EIA), a  
8 treponemal test. The RPR continued to be used as a confirmatory test as well as for monitoring  
9 response to therapy[15, 18]. In Calgary, the secondary confirmatory test was either the  
10 fluorescent treponemal antibody absorption test (FTA-ABS) or the line immunoassay (INNO-  
11 LIA)[19].

12  
13 Recurrent syphilis episodes were identified by a four-fold increase in RPR after a prior  
14 documented successful treatment course for syphilis and were evaluated and staged by an STI  
15 specialist (RR). Neurosyphilis was documented by a positive CSF-VRDL (Venereal disease  
16 research laboratory) on lumbar puncture as well as evaluated by an STI specialist (RR). HIV  
17 PrEP use was not extensively used in the community during the study period and any potential  
18 role seemed unlikely.

### 19 20 **Data Collection**

21 Detailed standardized information was collected by one physician (RL), through a  
22 comprehensive review of both SAC and CSTI charts and databases. Multiple data sources in

1 these records were accessed including nursing interviews, social work reports, self-administered  
2 questionnaires, laboratory reports, and physician notes.

3  
4 From the SAC database, we identified the number of syphilis tests performed yearly at the clinic  
5 per patient as well as the interval between tests. Demographic data was collected at the time of  
6 HIV diagnosis and incorporated into the SAC database. These data included: gender (i.e. male,  
7 female, transgendered), self-reported ethnicity (i.e. Caucasian, Indigenous,  
8 African/Caribbean/Black (ACB), Other) and most likely HIV exposure risk (i.e. MSM, HET-  
9 heterosexual sex, PWID (persons who inject drugs), and other).

10  
11 The stage of syphilis (i.e. primary, secondary, early latent, late latent) and symptomatology at  
12 presentation (i.e. rash, ulcer/lesion, flu-like illness, condylomata, lymphadenopathy, neurological  
13 (tinnitus/ocular), asymptomatic, other) were collected via review of CSTI charts. All episodes of  
14 syphilis were staged by an STI specialist (RR) based on both clinical and laboratory  
15 investigations. In the absence of symptoms, the staging of primary versus latent syphilis was  
16 based on the timing of rising RPR titers in relation to most recent prior titer. Prior history of  
17 comorbid infections including *Neisseria gonorrhoeae* and *Chlamydia trachomatis* were self-  
18 reported at the time of syphilis diagnosis.

19  
20 The initial RPR was documented at the time of syphilis diagnosis and recorded in CSTI charts.  
21 HIV viral load and CD4 counts were measured at the time of syphilis diagnosis and subsequently  
22 at the next routine HIV follow-up appointment. HIV viral suppression was defined as a plasma  
23 viral load <40 copies/mL. Treatment modalities (i.e. Benzathine Penicillin, Doxycycline,

1 Penicillin G) and response to therapy were reviewed retrospectively through a comprehensive  
2 chart review. All data was anonymized prior to analysis.

### 4 **Patient and Public Involvement**

5 No patients or public were involved in the present study. Our findings have been provided to  
6 local public health and will be used in broader STI control initiatives.

### 8 **Statistical Analysis**

9 Demographic and clinical factors of patients were compared using chi-square test. Viral load and  
10 CD4 counts prior to and following episode of syphilis infection were compared using linear  
11 mixed effect model while accounting for repeated measurement and more than one episode for  
12 some patients. Subgroup analyses were performed on neurosyphilis infections and those with  
13 recurrent episodes of syphilis. Patients not accessing care and individuals infected but lost to  
14 follow up or moving out of Alberta were not analyzed. All statistical analysis was performed  
15 using R (R Development Core Team, 2005). All charts were created with Microsoft Excel and R.

## 17 **RESULTS:**

### 18 **Demographics**

19 Between 2006 and 2016, there were 20,203 syphilis tests done on a total of 2,448 patients who  
20 attended at least one regular SAC visit during that time. On average, there were 180 days  
21 between each syphilis test per patient. The average number of syphilis screening tests that were  
22 done per patient each year over the 11-year period was 2.1. In 2006, the average number of tests



1 per year was 1.3, whereas in 2016 this was 2.8. For high risk patients (MSM), screening rates  
 2 were more frequent with the average testing over 11 years being 2.4 tests per year.

3  
 4 Of the 2,448 HIV-infected individuals at SAC and CSTI programs encompassing 15,175 person  
 5 years of follow up between 1/1/2006 and 12/31/2016, we identified 322 incident syphilis  
 6 infections, occurring in 267 different patients. There were 73 syphilis episodes in 73 patients that  
 7 were excluded. Of those excluded; 41 patients, while being tested in Alberta, had moved out of  
 8 province resulting in incomplete clinical data, and in 32 patients, there was inadequate basic  
 9 information available for study inclusion. We therefore analyzed 249 episodes in 194  
 10 individuals.

11  
 12 Of the 249 infections, 178 (72%) were first episode of a syphilis infection, whereas the  
 13 remaining 71 (28%) were recurrent episodes. The annual incidence rates of syphilis in our HIV-  
 14 infected population tripled from 2011, 8.08/1000 patient-years (95% confidence interval (CI):  
 15 4.14-14.75), to 27.04 per 1000 person-years (95% confidence interval (CI): 19.45-36.76) in  
 16 2016[3]. Prior history of STI's included; 32% of cases having a self-reported history of *Neisseria*  
 17 *gonorrhoeae* and 24% having had *Chlamydia trachomatis* infection. The characteristics of the  
 18 194 individuals included in this analysis are described in table 1.

19  
 20 **Table 1: Characteristics of HIV+ patients regularly followed at the Southern Alberta Clinic**  
 21 **between 1/1/2006 and 12/31/2016 comparing patients who were negative for syphilis (Syphilis**  
 22 **Neg) to patients who ever tested positive for syphilis (Syphilis Pos).**

	Syphilis Neg	Syphilis Pos	P-value
N (%)	2254 (92.1)	194 (7.9)	
<b>Age at HIV Diagnosis</b> (years)			
Mean (range)	35 (1-79)	35 (16-69)	0.893

1				
2				
3	1			
4	2	<30	813 (36.1)	75 (38.7)
5	3	30-39	802 (35.6)	66 (34.0)
6	4	40-49	438 (19.4)	37 (19.1)
7	5	≥50	201 (8.9)	16 (8.3)
8	6			
9	7	<b>Gender</b>		
10	8	Male	1675 (74.3)	183 (94.3)
11	9	Female	572 (25.4)	11 (5.6)
12	10	Transgendered	7 (0.3)	0 (0.0)
13	11			
14	12	<b>Self-reported Ethnicity<sup>1</sup></b>		
15	13	Caucasian	1259 (56.0)	140 (72.2)
16	14	Indigenous	216 (9.6)	6 (3.1)
17	15	ACB	536 (23.8)	24 (12.4)
18	16	Other	243 (10.8)	24 (12.4)
19	17			
20	18	<b>Most Likely HIV Exposure Category<sup>2</sup></b>		
21	19	MSM	915 (40.6)	145 (74.4)
22	20	HET	512 (22.7)	14 (7.2)
23	21	PWID	731 (32.4)	30 (15.6)
24	22	Other	96 (4.3)	5 (2.6)
25	23			
26	24			
27	25			
28	26			
29	27			
30	28			
31	29			
32	30			
33	31			
34	32			
35	33			
36	34			
37	35			
38	36			
39	37			
40	38			
41	39			
42	40			
43	41			
44	42			
45	43			
46	44			
47	45			
48	46			
49	47			
50	48			
51	49			
52	50			
53	51			
54	52			
55	53			
56	54			
57	55			
58	56			
59	57			
60	58			

<sup>1</sup>Indigenous people includes Aboriginal, Metis and Inuit; ACB includes African, Caribbean, Black; Other includes IndoAsian, Hispanic, East Asian, and other

<sup>2</sup>MSM=self-reported men who have sex with men identification; HET=self-reported heterosexual identification; PWID=self-reported intravenous drug use identification; Other HIV Risk factor behavior includes: blood transfusions, hemophiliac, neonatal, postnatal infection, unknown or not reported.

## 30 Symptomatology

### 31 Asymptomatic syphilis episodes

32 Just over half of the episodes (50.8%) of incident syphilis infections were asymptomatic and  
 33 identified by routine screening (Figure 1). RPR titers were higher in patients with symptomatic  
 34 versus asymptomatic syphilis (P=0.03) (Figure 2). The majority of episodes with an initial RPR  
 35 of 1:4 or less were asymptomatic (71%). Those with lower CD4 (<200 cells/mm<sup>3</sup>) counts at  
 36 syphilis diagnosis had no significant differences in symptomatology as opposed to those with  
 37 CD4 counts >200 cells/mm<sup>3</sup> (P= 0.65). Neither virologic suppression of HIV nor ART use  
 38 influenced the individual's likelihood to present with symptomatic syphilis.

### 1 *Symptomatic syphilis episodes*

2 The most common presenting symptom was rash (23%), followed by skin lesion or ulceration  
3 (18%). Uncommon presentations included lymphadenopathy, flu-like illness, condylomata lata  
4 and neurological symptoms (Figure 1). The most common presenting symptom in primary  
5 syphilis was skin ulceration/lesion (57%) and in those with secondary syphilis was a rash (76%).  
6 However, 15% of those diagnosed with secondary syphilis also complained of skin ulceration or  
7 lesion in addition to a rash. Although rare overall as presenting symptoms, lymphadenopathy  
8 (86%), flu like illness (50%) and condylomata (100%) were most seen in primary syphilis.

### 10 **Stage of Syphilis**

11 Both ART and virologic suppression of HIV had no association with the individual's stage of  
12 syphilis at diagnosis. Of those diagnosed with late latent syphilis, 98% had an initial RPR of 1:16  
13 or less. Patients with secondary syphilis tended to present with a higher RPR, 33% having an  
14 RPR of 1:256 or higher.

16 Since 2008, the proportion of late latent syphilis infections diagnosed among our HIV-infected  
17 patients in care had decreased from 44% to 4.4% (Figure 3). Caucasian individuals were more  
18 likely to present with primary (24%) or secondary (28%) syphilis ( $P < 0.001$ ), whereas the non-  
19 Caucasian population were more likely to present with latent disease (74%) ( $P < 0.001$ ). In  
20 males, the majority of infections were early latent (34%) and the minority being late latent  
21 (18%). However, in females 77% of infections were late latent.

### 23 **Effect of Syphilis on Markers of HIV**

1 As the interaction of HIV and syphilis infection may be bidirectional we explored CD4 and viral  
2 load response to syphilis infection. A significant decrease in CD4 count of 42.2 cells/mm<sup>3</sup>  
3 (P=0.004) was noted in association with syphilis coinfection (Figure 4). However, there was no  
4 change in HIV viral load noted in association with syphilis coinfection (P=0.47) (Figure 5).

### 6 **Effect of HIV on Markers of Syphilis**

7 Nearly half (49%) of all patients presented with RPR (non-treponemal) titers between 1:32-  
8 1:128. There were two episodes presenting with an initial RPR greater than 1:2048; both patients  
9 were not HIV virologically suppressed (HIV plasma viral load >1,000 copies/mL) at the time of  
10 syphilis infection (Figure 2). The individuals viral load (P=0.82) or CD4 count (P=0.48) did not  
11 appear to have any correlation with the initial RPR titer. We were unable to evaluate if the  
12 absence of ART had an impact on RPR titer due to the small number of patients not on ART  
13 (n=48).

### 15 **Recurrent Episodes of Syphilis**

16 In patients with recurrent syphilis infection, a trend (P=0.07) was noted favoring symptomatic  
17 presentation (62%). Rash and skin lesion/ulceration also remained the most common complaint  
18 (Figure 6). Recurrent episodes of syphilis were much less likely to be late latent disease (3%)  
19 and instead more likely to be primary (28%), secondary (28%) or early latent disease (39%). Of  
20 those with a recurrent syphilis episode, 29% had RPR titers over 1:256, compared to 18% in the  
21 study population. Only 10% of the patients with prior syphilis exposure had an initial RPR less  
22 than 1:4 compared to 32% in the study population, however this did not reach significance  
23 (P=0.604).

1  
2  
3 1  
4  
5 2 **Neurosyphilis**  
6  
7  
8 3 CNS involvement was noted in 10/249 (4%) episodes with a positive CSF-VDRL on lumbar  
9  
10 4 puncture. Ocular symptoms with blurred vision or painless visual loss occurred in four patients,  
11  
12 5 tinnitus in three patients and three were asymptomatic. Nine patients were male and Caucasian  
13  
14 6 with eight being >40 years old. Eight were initial syphilis episodes and two were reinfections.  
15  
16  
17 7 Seven of the ten patients were on ART, five were virologically suppressed with seven having a  
18  
19 8 CD4 count > 500 cells/mL. The RPR titer at diagnosis was  $\geq 1:32$  in all episodes of CNS  
20  
21  
22 9 involvement with five having an RPR titer of  $\geq 1:512$  and two of these episodes diagnosed with  
23  
24 10 initial RPR titers of 1:8192. These RPR titers were much higher than any other symptom  
25  
26 11 presentation ( $P < 0.001$ ) (Figure 2). All patients with CNS involvement were treated  
27  
28 12 successfully, based on both clinical and serologic response, with intravenous penicillin G for 14  
29  
30  
31 13 days.

## 32 33 34 35 15 **Treatment**

36  
37 16 A standard three-week course of weekly intramuscular injections of Benzathine penicillin  
38  
39 17 (2.4MU per dose) was used for 77% of the patients, while 10% received an oral course of  
40  
41  
42 18 doxycycline, and 10% received a combination of the two medications. Successful completion of  
43  
44 19 the full course of treatment was achieved in 94% (with 5% requiring retreatment from inadequate  
45  
46 20 initial adherence and 1% never completing their full course).

## 47 48 49 50 51 22 **DISCUSSION:**

1 Our introduction in 2006 of syphilis screening to accompany routine HIV viral load testing  
2 allowed for the identification and analysis of incident syphilis infections in the HIV population in  
3 care in Calgary, Alberta. Our results confirm prior findings that co-infection with HIV can result  
4 in atypical or severe syphilis presentations[8-11]. Compared to non HIV-infected populations,  
5 prior studies have found higher rates of asymptomatic primary syphilis, which may result in  
6 missed diagnosis and increased episodes of secondary syphilis[11, 20]. In our study population,  
7 50.8% (135) syphilis episodes were asymptomatic at presentation, including 21% (10) of the  
8 primary syphilis infections. Braun et al. recently published a study evaluating symptoms of  
9 syphilis in 19 HIV-infected individuals and found the rate of asymptomatic syphilis infections in  
10 HIV-infected individuals to be 40%[21]. Routine syphilis screening has been confirmed to be  
11 effective in detecting early asymptomatic syphilis in HIV-infected outpatients[20].

12  
13 Our study demonstrated a decline in latent syphilis between 2008 (44%) and 2016 (4%). In 2008,  
14 the high numbers of latent syphilis may be reflective of a change to the testing algorithm for  
15 syphilis, from an initial RPR to enzyme immunoassay (EIA), resulting in an improved test  
16 sensitivity and the identification of latent syphilis[18, 19]. While latent episodes have been  
17 steadily declining since 2013, the number of primary syphilis diagnoses are increasing. Through  
18 regular syphilis screening in this HIV-infected population, earlier detection of syphilis in its  
19 primary stage has been achieved, leading to prompt therapy, which may decrease ongoing  
20 syphilis transmission[4].

21  
22 The interaction of HIV and syphilis infection appears to be bidirectional with effects noted on  
23 both HIV and syphilis serologic and clinical markers[11]. Prior studies have reported that

1 syphilis infection may increase HIV viral load and decrease CD4 count[22-25]. We observed a  
2 statistically significant decrease in CD4 count associated with incident syphilis infections, but no  
3 change in viral load was noted. This difference in findings compared with past studies may in  
4 part, be explained by the majority of our patients being on ART, which are perhaps more potent  
5 in suppressing viral replication.

6  
7 An increased prevalence of neurologic manifestations has been reported in HIV-infected  
8 individuals[2, 4]. Approximately one third of any patient with early syphilis will have  
9 treponemal invasion into their CNS regardless of their HIV status[4]. However, an increased rate  
10 of early neurosyphilis among HIV-infected individuals has been noted and may be linked to the  
11 patient's inability to control the CNS infection rather than increased invasion into the CNS[4,  
12 25]. Our data revealed 10/249 (4%) of the syphilis episodes diagnosed in our HIV-infected  
13 cohort were neurosyphilis.

14  
15 Neurosyphilis is more likely to be asymptomatic in HIV co-infected individuals and therefore a  
16 more difficult diagnosis[4]. Three of our ten neurosyphilis episodes were indeed asymptomatic.  
17 As a response to the absence of symptoms, CDC guidelines recommend HIV-infected  
18 individuals who receive a diagnosis of late latent syphilis, unknown duration of disease, have  
19 neurologic symptoms or treatment failure should undergo CSF evaluation[4, 26]. It is  
20 controversial whether all HIV co-infected individuals require evaluation for neurosyphilis at the  
21 time of syphilis diagnosis[4].

22

1  
2  
3 1 Recent data suggests that there is an association with RPR titers  $\geq 1:32$  and laboratory defined  
4  
5 2 neurosyphilis (sensitivity of 100%, specificity of 40%)[24, 25]. This is in keeping with our study  
6  
7 3 findings, deducing that lumbar puncture could be restricted to the subgroup of patients with  
8  
9 4 neurologic manifestation or a serum RPR of  $\geq 1:32$ [27, 28]. Prior studies have found that patients  
10  
11 5 with CD4 counts  $< 350\text{mm}^3$ , may be at increased risk for neurosyphilis, however we identified no  
12  
13 6 specific correlation[4, 28, 29]. We did note that five of the individuals with neurosyphilis were  
14  
15 7 not HIV virologically suppressed, suggesting that there may be a link between increased HIV  
16  
17 8 viral loads and neurosyphilis, however this requires further study.  
18  
19  
20  
21  
22 9

23  
24 10 The key strength of our study is the detailed longitudinal analysis of clinical, serologic and  
25  
26 11 treatment outcomes in our population that is made possible by the highly centralized HIV and  
27  
28 12 STI care programs in our region. The study population, while comprehensive, is from a single  
29  
30 13 regional area and may not be generalizable to populations elsewhere. Rates of unprotected sexual  
31  
32 14 activity, prevalent HIV and syphilis infections, and access to care varies between centers and  
33  
34 15 populations, therefore our rates and identification methods may not match others. Limitations of  
35  
36 16 our study include a potential underestimation of the clinical impact of syphilis in this HIV-  
37  
38 17 infected population as patients not accessing care and individuals infected but lost to follow up  
39  
40 18 or who moved from Alberta were not analyzed.  
41  
42  
43  
44  
45 19

## 20 **CONCLUSIONS:**

21 Through routine screening of an HIV-infected population engaged in care, many asymptomatic  
22 syphilis episodes were identified and treated resulting in a shift in diagnostic stage of syphilis  
23 infection from latent to primary and a theoretical decrease in ongoing transmission. Individuals



1 with symptomatic syphilis infections were more likely to have higher RPR titers and those with  
2 highest RPR titers were at greater risk of having neurosyphilis. ART, CD4 count and virologic  
3 suppression of HIV had no association with the individual's stage of syphilis or symptoms at  
4 diagnosis. Syphilis infection was associated with a temporary decrease in CD4 count with no  
5 impact on HIV viral load. As the rates of syphilis rise among the HIV-infected population,  
6 ongoing vigilance in screening and treatment is required in addition to further examination of co-  
7 infection interactions.

#### 8 **FIGURE LEGENDS:**

9 Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected  
10 population.

11 Figure 2: Percentage of syphilis episodes divided by symptom at presentation based on initial  
12 RPR titer. Individuals who had symptoms compared to those that did not were more likely to  
13 have a higher initial RPR ( $P=0.0339$ ). The most common symptoms were rash and ulcer/lesion  
14 with flu-like illness, condylomata and lymphadenopathy being relatively rare. Those with  
15 neurologic symptoms had a significant elevation of their initial RPR titers compared with all  
16 other symptoms ( $P<0.001$ ) and there were no cases of neurosyphilis with RPR titers less than  
17 1:32 dilutions.

18 Figure 3: There is an increased number of incident syphilis infections among HIV positive  
19 individuals who are active in care programs from 2006-2016. There is an apparent trend of  
20 decreased proportion of late latent disease.

1  
2  
3 1 Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up  
4  
5 2 appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2  
6  
7 3 cells/mm<sup>3</sup> (P =0.004).  
8  
9

10  
11 4 Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation  
12  
13 5 in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of  
14  
15 6 syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis  
16  
17 7 co-infection (P =0.47).  
18  
19

20  
21 8 Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by  
22  
23 9 recurrent infections. There is a trend demonstrating that individuals with recurrent syphilis  
24  
25 10 infections were more likely to be symptomatic on presentation, however this did not reach  
26  
27 11 significance (P=0.0799).  
28  
29

30  
31  
32  
33 13 **DECLARATIONS:**  
34  
35

36  
37 14 **Ethics approval and consent to participate:** Ethics approval was obtained through the  
38  
39 15 University of Calgary Bioethics committee as a quality assurance project through A Project  
40  
41 16 Ethics Community Consensus Initiative (ARECCI). Approval was granted both verbally and  
42  
43 17 written on Aug 23, 2016.  
44  
45

46  
47 18 **Data sharing:** The datasets generated and/or analyzed during the current study are not publicly  
48  
49 19 available due to patient confidentiality. The sensitive nature of this information as well as the  
50  
51 20 relatively small number of patients included in this dataset may lead it to be identifying and  
52  
53 21 therefore does not allow this dataset to be made public.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 1 **Funding:** No funding was received for this work.  
4  
5

6  
7 2 **Conflicts of interest:** We have no relevant conflicts of interest to disclose.  
8  
9

10  
11 3 This work was previously presented at ID week 2017 in San Diego, California.  
12

13  
14 4 **Authors' contributions:** RL, RR, HK and JG were involved in study design, data extraction,  
15  
16 5 data analysis, drafting and final review of this work. SR, MP, and QV were involved in data  
17  
18 6 extraction, data analysis and final review of this work. All authors read and approved the final  
19  
20 7 manuscript.  
21  
22

23  
24 8 **Acknowledgements:** We would like to thank all clinic staff at SAC and CSTI and especially  
25  
26 9 Janet Furseth and Jennifer Gratrix for their help in the project.  
27  
28

29  
30 10

31  
32 11 **REFERENCES:**  
33

- 34  
35 12 1. World Health Organization, Dept of Reproductive Health and Research. Global incidence  
36  
37 13 and prevalence of selected curable sexually transmitted infections – 2008. 2012.  
38  
39 14 Available at: <http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/>.  
40  
41 15 Date accessed: Dec 6, 2017.  
42  
43  
44 16 2. Karp G, Schleffer F, Jotkowitz A, *et al.* Syphilis and HIV co-infection. *Eur. J. Intern.*  
45  
46 17 *Med* 2009;**20**:9-13.  
47  
48 18 3. Lang R, Read R, Krentz HB, *et al.* Increasing incidence of syphilis among patients  
49  
50 19 engaged in HIV care in Alberta, Canada: a retrospective clinic-based cohort study. *BMC*  
51  
52 20 *Infect Dis* 2018;**18**:125.  
53  
54  
55 21 4. Zetola NM, Klausner JD. Syphilis and HIV Infection: An Update. *CID* 2007;**44**:1222-8.  
56  
57  
58  
59  
60

- 1 5. R. v. Mabior, 2012 SCC 47, [2012] 2 S.C.R. 584. Available at: [https://scc-](https://scc-csc.lexum.com/scc-csc/scc-csc/en/item/10008/index.do)  
2 csc.lexum.com/scc-csc/scc-csc/en/item/10008/index.do. Date accessed: Dec 1, 2017.
- 3 6. Kouyos RD, Hasse B, Calmy A, *et al.* Increases in Condomless Sex in the Swiss HIV  
4 Cohort Study. *Open Forum Infect Dis* 2015;**2**(2):ofv077.
- 5 7. Rolfs RT, Joesoef MR, Hendershot EF, *et al.* A randomized trial of enhanced therapy for  
6 early syphilis in patients with and without human immunodeficiency virus infection. The  
7 Syphilis and HIV Study Group, *N Engl J Med* 1997;**337**:307-15.
- 8 8. Rompalo AM, Joesoef MR, O'Donnell JA, *et al.* Clinical Manifestations of Early  
9 Syphilis by HIV Status and Gender: Results of the Syphilis and HIV Study. *Sex Transm*  
10 *Dis* 2001;**28**(3):158-65.
- 11 9. Marra CM, Tantalo LC, Sahi SK, *et al.* Reduced Treponema pallidum-Specific Opsonic  
12 Antibody Activity in HIV-Infected Patients with Syphilis. *J Infect Dis* 2016;**213**:1348-54.
- 13 10. Collis TK, Celum CL. The Clinical Manifestations and treatment of Sexually Transmitted  
14 Diseases in Human Immunodeficiency Virus-Positive Men. *Clin Infect Dis* 2001;**32**:611-  
15 22.
- 16 11. Lynn WA, Lightman S. Syphilis and HIV: a dangerous combination. *Lancet Infect Dis*  
17 2004;**4**:456-66.
- 18 12. McCoy SI, Eron JJ, Kuruc JD, *et al.* Sexually transmitted infections among patients with  
19 acute HIV in North Carolina. *Sex Transm Dis* 2009;**36**(6):372-4.
- 20 13. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and  
21 practice: the contribution of other sexually transmitted diseases to sexual transmission of  
22 HIV infection. *Sex Transm Infect* 1999;**75**:3-17.

- 1  
2  
3 1 14. Rekart ML, Ndifon W, Brunham RC, *et al.* A double-edged sword: does highly active  
4 antiretroviral therapy contribute to syphilis incidence by impairing immunity to  
5  
6 2  
7  
8 3  
9  
10 4 15. Branger J, Van Der Meer JT, Van Ketel RJ, *et al.* High Incidence of Asymptomatic  
11 Syphilis in HIV-Infected MSM Justifies Routine Screening. *Sex Transm Dis*  
12  
13 5  
14 2009;**36**(2):84-5.  
15 6  
16  
17 7 16. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment  
18 Guidelines, 2015. Available at: <https://www.cdc.gov/std/tg2015/tg-2015-print.pdf>. Date  
19 8  
20 accessed: Feb 26, 2017.  
21 9  
22  
23 10 17. European AIDS Clinical Society (EACS). Guidelines Version 9.0. 2017. Available at:  
24  
25  
26 11  
27 [http://www.eacsociety.org/files/guidelines\\_9.0-english.pdf](http://www.eacsociety.org/files/guidelines_9.0-english.pdf). Date accessed Feb 26, 2017.  
28  
29 12 18. Ratnam S. The laboratory diagnosis of syphilis. *Can J Infect Dis Med Microbiol*  
30  
31 13  
32 2005;**16**(1):45-51.  
33 14 19. Public Health Agency of Canada. Canadian Guidelines on Sexually Transmitted  
34 Infections: Syphilis. 2014. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti->  
35 15  
36  
37 16  
38 [ldcits/section-5-10-eng.php](http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-). Date accessed: Dec 6, 2017.  
39  
40 17 20. Cohen CE, Winston A, Asboe D, *et al.* Increasing detection of asymptomatic syphilis in  
41 HIV patients. *Sex Transm Infect* 2005;**81**:217-219.  
42 18  
43  
44 19 21. Braun DL, Marzel A, Steffens D, *et al.* High rates of subsequent asymptomatic STIs  
45 and risky sexual behavior in patients initially presenting with primary HIV-1 infection.  
46  
47 20  
48  
49 21  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 1 22. Buchacz K, Patel P, Taylor M, *et al*. Syphilis increases HIV viral load and decreases CD4  
4 cell counts in HIV-infected patients with new syphilis infections. *AIDS*  
5 2  
6 cell counts in HIV-infected patients with new syphilis infections. *AIDS*  
7 3  
8 2004;**18**(15):2075–9.  
9  
10 4 23. Palacios R, Jimenez-Onate F, Aguilar M, *et al*. Impact of syphilis infection on HIV viral  
11 load and CD4 cell counts in HIV-infected patients. *J Acquir Immune Defic Syndr* 2007;  
12 5  
13 load and CD4 cell counts in HIV-infected patients. *J Acquir Immune Defic Syndr* 2007;  
14 6  
15 **44**(3):356–9.  
16  
17 7 24. Sadiq ST, McSorley J, Copas AJ, *et al*. The effects of early syphilis on CD4 counts and  
18 HIV-1 RNA viral loads in blood and semen. *Sex Transm Infect* 2005;**81**:380–5.  
19 8  
20  
21 9 25. Rolfs RT, Joesoef MR, Hendershot EF, *et al*. A randomized trial of enhanced therapy for  
22 early syphilis in patients with and without human immunodeficiency virus infection. The  
23 Syphilis and HIV Study Group, *N Engl J Med* 1997;**337**:307-15.  
24 10  
25  
26 11 26. Workowski KA, Berman SM. Centers for Disease C, Prevention. Sexually transmitted  
27 diseases treatment guidelines. *MMWR Recomm Rep* 2010;**59**(12):1-110.  
28 12  
29  
30 13 27. Libois A, De Wit S, Poll B, *et al*. HIV and syphilis: when to perform a lumbar puncture.  
31 *Sex Transm Dis* 2007;**34**(3):141-4  
32  
33 14 28. Marra CM, Maxwell CL, Smith SL, *et al*. Cerebrospinal fluid abnormalities in patients  
34 with syphilis: association with clinical and laboratory features. *J Infect Dis*  
35 15  
36 *Sex Transm Dis* 2007;**34**(3):141-4  
37  
38 16 29. Ghanem KG, Moore RD, Rompalo AM, *et al*. Neurosyphilis in a clinical cohort of HIV 1  
39 with syphilis: association with clinical and laboratory features. *J Infect Dis*  
40 17  
41  
42 18 2004;**189**:369-76.  
43  
44 19 29. Ghanem KG, Moore RD, Rompalo AM, *et al*. Neurosyphilis in a clinical cohort of HIV 1  
45 infected patients. *AIDS* 2008;**22**(10):1145-51.  
46  
47 20  
48  
49 21

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Percentage of Syphilis Episodes Divided by Symptoms at time of Positive Syphilis Testing




Figure 1: Percentage of episodes of syphilis diagnosed based on symptoms in a HIV-infected population.

127x71mm (300 x 300 DPI)

review only




Figure 2: Percentage of syphilis episodes divided by symptom at presentation based on initial RPR titer. Individuals who had symptoms compared to those that did not were more likely to have a higher initial RPR ( $P=0.0339$ ). The most common symptoms were rash and ulcer/lesion with flu-like illness, condylomata and lymphadenopathy being relatively rare. Those with neurologic symptoms had a significant elevation of their initial RPR titers compared with all other symptoms ( $P<0.001$ ) and there were no cases of neurosyphilis with RPR titers less than 1:32 dilutions.

71x40mm (600 x 600 DPI)






Figure 3: There is an increased number of incident syphilis infections among HIV positive individuals who are active in care programs from 2006-2016. There is an apparent trend of decreased proportion of late latent disease.

71x40mm (300 x 300 DPI)




Figure 4: Scatter plot of CD4 count at syphilis diagnosis versus CD4 count at follow up appointment after treatment of syphilis. CD4 count was noted to decrease by an average of 42.2 cells/mm<sup>3</sup> (P =0.004).

127x127mm (300 x 300 DPI)




Figure 5: Scatter plot of viral load (adjusted on a logarithmic scale to account for wide variation in values) at syphilis diagnosis versus viral load at follow up appointment after treatment of syphilis. Viral load was noted to increase by an average of 3.09 copies/mL in relation to syphilis co-infection (P =0.47).

127x127mm (300 x 300 DPI)




Figure 6: The percentage of syphilis episodes comparing initial symptom presentation divided by recurrent infections. There is a trend demonstrating that individuals with recurrent syphilis infections were more likely to be symptomatic on presentation, however this did not reach significance (P=0.0799).

71x40mm (300 x 300 DPI)

## STROBE Statement—checklist of items that should be included in reports of observational studies

	Item No	Recommendation
<b>Title and abstract</b> Page 1,2	1	(a) Indicate the study's design with a commonly used term in the title or the abstract  (b) Provide in the abstract an informative and balanced summary of what was done and what was found
<b>Introduction</b>		
Background/rationale Page 4	2	Explain the scientific background and rationale for the investigation being reported
Objectives Page 5	3	State specific objectives, including any prespecified hypotheses
<b>Methods</b>		
Study design Page 5	4	Present key elements of study design early in the paper
Setting Page 6	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection
Participants Page 5	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants  (b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case
Variables Page 5,6, 7	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable
Data sources/ measurement Page 6,7	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group
Bias Page 7	9	Describe any efforts to address potential sources of bias
Study size Page 8	10	Explain how the study size was arrived at
Quantitative variables Page 7	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why
Statistical methods Page 7	12	(a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy  (e) Describe any sensitivity analyses

Continued on next page

**Results**

Participants Page 8	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed (b) Give reasons for non-participation at each stage (c) Consider use of a flow diagram
Descriptive data Page 8,9	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders (b) Indicate number of participants with missing data for each variable of interest (c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)
Outcome data Page 8	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time <i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> —Report numbers of outcome events or summary measures
Main results Page 10, 11, 12	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses Page 12, 13	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses

**Discussion**

Key results Page 13, 14, 15	18	Summarise key results with reference to study objectives
Limitations Page 3	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias
Interpretation Page 16	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence
Generalisability Page 3	21	Discuss the generalisability (external validity) of the study results

**Other information**

Funding Page 18	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based
--------------------	----	---

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).